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Abstract

NOVEL STRATEGIES IN CARDIOPROTECTION AGAINST
ISCHEMIA/REPERFUSION INJURY
By Fadi N. Salloum, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2005
Major Director: Rakesh C. Kukreja
Professor
School of Medicine

Cell damage represents a major pathomechanism in many diseases of high clinical
interest, such as myocardial infarction (MI), where it plays an important role in ischemiareperfusion (I/R) injury. Considerable progress has been made towards identifying
physiological and pharmacological agents that play a key role in myocardial
preconditioning against I/R injury and also elucidating the molecular changes leading to
such protection.
Second messengers in cellular signaling pathways, such as cGMP have been well
implicated as key players in ischemic and pharmacological preconditioning (PC) of the
xii

xiii
heart. Phosphodiesterase type 5 (PDE-5) is an enzyme that specifically hydrolyzes cGMP
thereby decreasing its tissue concentration. Sildenafil is a potent selective inhibitor of
PDE-5 and therefore allows the accumulation of cGMP in several tissues shown to express
PDE-5, including pulmonary and coronary arteries. We initially hypothesized that
vasodilation induced by sildenafil may release several endogenous mediators including
adenosine, bradykinin or nitric oxide (NO), that may trigger a signaling cascade leading to
protection against ischemia/reperfusion (I/R) injury. Our results show that sildenafil, at a
clinically relevant dose, induced powerful acute and delayed cardioprotection against I/R
injury in an in vivo rabbit model via opening of mitoKATP channels. The acute
cardioprotective effect of sildenafil was dependent on activation of protein kinase C in
rabbits. Moreover, we observed that sildenafil induced delayed PC by NO produced
through activation of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide
synthase (eNOS) in the mouse heart. The expression of iNOS/eNOS was regulated by
ERK phosphorylation and the delayed protection against I/R was blocked by PD98059, a
selective ERK inhibitor. Furthermore, sildenafil-induced delayed protection was abolished
in the intact heart as well as adult myocytes derived from adenosine A1 receptor knock-out
mice suggesting an essential role of A1 receptor in protection. Taken together, these
studies suggest that sildenafil is a powerful tool to reduce I/R injury in the animal models.
Future clinical studies with relatively safe and effective PDE-5 inhibitors may have an
enourmous impact on the use of these compounds in reducing I/R injury in the heart and
other organs.

CHAPTER 1

INTRODUCTION
1. Background

Determining the mechanism(s) of cardioprotection in diseased hearts is of high
significance because the mortality and morbidity of heart disease are increasing around the
world, and there is a continuous demand for safe and efficient preventive or therapeutic
strategies. Following the development and application of percutaneous transluminal
coronary angioplasty (PTCA) [4] and percutaneous transluminal coronary recanalization
(PTCR) in the clinical setting, treatment of patients with acute coronary syndrome has
made significant progress [5]. As a result, mortality related to acute myocardial infarction
has decreased, but the functional recovery of reperfused hearts is unfortunately less than
expected, resulting in an increase of patients with chronic ischemic heart failure [6]. As of
yet, no sufficiently effective drugs to decrease infarct size and prevent cardiac remodeling
in patients with acute myocardial infarction or ischemic heart disease have been identified .
Cardiologists involved in the management of patients with acute coronary
syndrome, including severe unstable angina and acute myocardial infarction, occasionally
used to report "the cardiac warm-up phenomenon" [7], in which patients with at least one
episode of angina showed less severe ischemic damage after subsequent exposure to a
1
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longer period of ischemia. In 1986, Murry et al. [1] first documented this phenomenon
experimentally and termed it "ischemic preconditioning" (PC). Following this initial
report, numerous studies were performed using various tissues and animals (e.g., liver [8],
kidney [9], brain [10], and endothelial cells [11]). PC was shown effective against
subsequent lethal ischemic insults in all models. More importantly, PC has also been
shown to occur in humans by some clinical studies [11]. This realization is highly
significant due to the possibility of transferring some or all of the basic research findings
from experiments involving PC to the clinical forefront in order to minimize infarct size
resulting from ischemic injury in patients with cardiovascular disease. Brief periods of
ischemia that cause preconditioning must occur prior to sustained ischemia to achieve
cardioprotection, but induction of myocardial ischemia is not a practical treatment for
patients with ischemic heart disease or those at risk of cardiovascular disease. Therefore, it
is important to determine the mechanisms underlying ischemic preconditioning in order to
devise new strategies effective against ischemic insults. Identifying some of the triggers,
mediators, and effectors of ischemic preconditioning would make it much easier to develop
more effective therapeutic interventions for acute coronary syndrome. Accordingly,
research in this field has been aiming at recognizing the histological, biochemical, and
physiological changes in the myocardium induced by ischemia in order to provide ideas
about the cellular mechanisms of ischemic preconditioning. Thus far, intensive research
has led to considerable progress in understanding the fundamental nature of ischemic
preconditioning and many of the potential pathways involved.

3

2. Windows of Protection
Soon after the original studies on ischemic PC revealed its potent cardioprotective
effect against I/R injury, independent reports from two laboratories in 1993 demonstrated
that the cardioprotective effect of ischemic preconditioning on infarct size was still
detectable for 24 hr after preconditioning and was associated with increased expression of
high molecular weight heat shock proteins (HSPs) [12, 13]. Because Kuzuya et al. [12]
also found that the infarct-limiting effect of preconditioning dissipated between 3 and 12 hr
after a brief period of ischemia, these two periods of cardioprotection were then referred to
as the "first window" and "second window", respectively, which are now known as "early
phase (or classical)" and "late phase" preconditioning. Subsequent research on the late
phase of cardioprotection afforded by PC also showed that it can persist for up to 72 hr
after preconditioning [14]. Thereafter, studies on PC focused on investigation of the
subcellular mechanisms, with the aim of devising new methods for application to
pharmacological preconditioning and for new clinical therapies to control acute myocardial
infarction and the resulting damage to the myocardium.
Interestingly, although different mechanisms may be involved in their mediation of
cardioprotection, the "early phase" and "late phase" of PC were reported to share some
trigger mechanisms. However, whereas the early phase is dependent on reactions that
occur very rapidly, such as direct activation of ion channels or phosphorylation of enzymes
and proteins, the late phase involves processes that require a longer period to occur such as
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modulation of the genes regulating channel proteins, receptor proteins, enzymes, molecular
chaperon proteins, or immune factors. So, in other words, it is quite interesting how these
two types of cardioprotection that occur at different time windows might share certain
triggers, mediators, and effectors.
For the purpose of the current discussion, we decided to individually describe the cellular
mechanism(s) involved in each of the two phases of PC.

3. Early phase PC: Cellular mechanisms
Adenosine
A little over a decade ago, a study showed that inhibition of the adenosine receptor
by administration of 8-p-sulfophenyl theophylline (8-SPT) prior to sustained ischemia was
able to abolish the protective effect of ischemic preconditioning in a rabbit model [15].
This report suggested that adenosine was a strong candidate as an agent for
pharmacological preconditioning and a trigger factor for ischemic preconditioning.
Taken together with the facts that the adenosine A1 receptor is one of the typical G-proteincoupled receptors (GPCRs) that have seven transmembrane domains, and that the
intracellular Ca2+ concentration rises soon after the onset of ischemia, it was hypothesized
that the subsequent cardioprotective response to an adenosine A1 receptor-derived stimulus
is related to both G-protein signals and Ca2+. As a result of myocardial ischemia, there is
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an immediate depletion in the ATP that is available for the cardiac cells [16] and as a
consequence adenosine is released [17] to interact with its receptors. In this respect, it was
believed that brief episodes of I/R would cause the release of adenosine and allow the
interaction with its receptors to “precondition” the myocardium against future ischemic
insults. Moreover, intracoronary infusion of adenosine in the isolated rabbit heart [18] or 2chloro-N6-cyclopentyladenosine (CCPA) in the isolated mouse heart prior to sustained I/R
demonstrated a marked decrease in infarct size when compared to control animals. In
addition, intravenous administration of another adenosine agonist, R-phenylisopropyl
adenosine (R-PIA) also produced similar results following sustained I/R. Furthermore, in
a study performed on transgenic mice, it was shown that over-expression of cardiac A1
adenosine receptor provided protection against I/R injury. There appears to be a dose
dependent manner in which these adenosine receptor agonists operate. Whereas three
doses of CCPA significantly reduced infarct size in the rabbit heart [19, 20]; continuous
adenosine A1 receptor activation with a chronic infusion of CCPA causes down-regulation
of the signaling cascade and the loss of the protective effect [21].

Despite these

observations, the intermittent administration of CCPA 10 day period did in fact confer
cardioprotection 48 hours after the last dosing [22].

Protein Kinase C (PKC)
Protein kinase C (PKC) was first described as a calcium-activated, phospholipidsdependent serine/threonine protein kinase. PKC is activated by diacylglycerol (DAG)
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hydrolyzed from phosphatidylinositol (PI) by phospholipase C (PLC) under different cellsignaling systems and has been an attractive intracellular receptor for tumor-promotor
phorbol esters. Despite the fact that PKC has been implicated as a protein kinase, further
molecular studies revealed that it belongs to a family of serine/threonine-specific protein
kinases and is involved in diverse cellular functions, including cell proliferation, tumor
promotion, differentiation, and apoptotic cell death.
PKC consists of at least 11 isoenzymes with selective tissue distribution, activators, and
substrates. Some of the isoenzymes are classified as classical or conventional PKC, which
require phospholipids, DAG, or phorbol ester and calcium, and others were classified as
novel PKC which share the same requirements with conventional PKC with the exception
of calcium. More recently, a different class of PKC emerged and that is the atypical PKC
which depends on phospholipid only.
Classical PKCs are activated by DAG and calcium in the presence of phosphatidylserine
(PS) and constitutively present in the membrane as follows: (i) DAG and inositol-1,4,5triphosphate (IP3) are generated from plasma membrane–associated phosphatidylinositol4,5-diphosphate (PIP2) by the activation of PLC; (ii) Ca2+ is released from an intracellular
storage pool stimulated by IP3; (iii) Ca2+ is bound to the C2 region of PKC and the enzyme
is subsequently translocated to the plasma membrane where (4) it is activated by DAG and
PS. Phorbol ester, in this model, would mimic the action of DAG, and, by its persistence in
the cellular membrane, lead to the long-term activation of PKC. As mentioned, nPKCs do
not need Ca2+ for activation, but they do require DAG/PS or phorbol ester/PS. These
processes are quite rapid, taking place in seconds or minutes, so that a more pronounced
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activation of PKC is required for cellular response to growth factors, cytokines, and
phorbol ester. Sustained activation of PKC is obtained by the long-term generation of
DAG from phosphatidylcholine by phospholipase D (PLD). Phosphatidylcholine is
hydrolyzed to choline and phosphatidic acid that is then converted to DAG by
phosphomonoesterase, thereby activating PKC. Intriguingly, PLD is activated by PKC
activators such as TPA and PKC itself. Furthermore, unsaturated fatty acids, such as oleic,
linoleic, linolenic, and arachidonic acid, and lysophosphatidic acid produced from
phosphatidylcholine by phospholipase A2, have been shown to enhance the activation of
PKC by DAG. Cytokines such as interleukin (IL)-3 and IL-1 induce phosphatidylcholine
hydrolysis, but not inositol phospholipids turnover; thus, the signal-induced production of
a distinct second messenger or activator may decide which PKC isoform becomes
activated or not.
Evidence for a significant role for PKC-α in the prevention of the apoptotic process is
increasing. Phosphorylation and activation of PKC- α are blocked by ceramide via
activation of okadaic acid–sensitive protein phosphatase (ceramide activated protein
phosphatase [CAPP]). Ceramide also inhibits both the translocation of PKC- α from the
cytosol to the particulate fraction and activation of PLD, interfering with PKC-mediated
activation of PLD. Cell permeable C2-ceramide inhibits activation of PLD and decreases
PKC- α activity. PKC- α may prevent apoptosis via activation of Bcl-2, as (1) ceramideinduced apoptosis is prevented by Bcl-2; (2) cPKC-mediated phosphorylation of Bcl-2 at
serine 70 functionally suppresses apoptosis; and (3) PKC- α co-localizes with Bcl-2 at the
mitochondrial membrane and phosphorylates it, thereby preventing progression of the
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apoptotic sequence. PKC-ε is also postulated to function as a suppressor of apoptosis,
because Bcl-2 is a substrate of PKC- ε. Overexpression of PKC- ε in human IL-3–
dependent TF-1 cells suppresses apoptosis induced by withdrawal of the cytokine via
induction of Bcl-2 expression. PKC- ε appears to be inhibited in TNF-α-, Fas-, and
ceramide-induced apoptosis, where the ε isoform is displaced from the particulate fraction
to the cytosol.
Ytrehus et al. [23] found that inhibition of PKC abolishes the limitation of infarct size by
pretreatment with adenosine or by ischemic preconditioning, suggesting that PKC plays a
pivotal role in the cardioprotective effect of preconditioning. Because PKC can be
activated by either ischemia or by extracellular stimuli such as catecholamines (α1adrenoceptor stimulation), lipopolysaccharide (LPS), and PMA [24 and 25], thus leading
to cardioprotection [26], it has come to be recognized as a major mediator of ischemic
preconditioning.
On the other hand, it has been reported that transient Ca2+ overload prior to sustained
ischemia also has the same protective effect as ischemic preconditioning [25].
Furthermore, the cardioprotective effect of PKC is abolished by GF109203X, a selective
inhibitor of Ca2+-dependent PKC (classical PKC) [27]. Because PKC-α is Ca2+-dependent,
these data suggest that triggering of the early phase preconditioning may be closely
associated with transient changes of intracellular Ca2+ during a brief period of ischemia.
While investigations were performed to identify the responsible subtype(s) of PKC in a
dog model [28] and a rat model [29], it was found that PKC-α mediates cardioprotection
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due to preconditioning in dogs, while other isozymes such as PKC-δ [30, 31 and 32] or
PKC-ε [33] have been detected in smaller animals.
Ischemic PC, as initiated by brief separate episodes of I/R, causes the release of
endogenous compounds such as adenosine, bradykinin, catecholomines, opioids which in
turn instigate signaling cascades leading to activation of PKC. PKC can also be activated
by reactive oxygen species which are known to be generated during short episodes of
ischemia especially at the onset of reperfusion. PKC potentially activates certain
transcription factors which play an important role in the synthesis of several proteins
including indcible nitric oxide synthase (iNOS), antioxidants, Bcl-2 and stress proteins.
iNOS generates NO and hence leads to the formation of cGMP from guanylyl cyclase
(GC), and cGMP in turn may activate protein kinase G (PKG) leading to opening of
mitochondrial KATP channels. By preventing calcium overload and preservation of ATP,
opening of these channels causes cardioprotection against I/R injury.
Administration of PKC agonists in the isolated rat heart resulted in myocardial
preconditioning [34]. However, PKC inhibitors given at the end of the ischemic PC period
in vivo [35] blocked the protection of PC. This reveals that there is a critical period at
which PKC exerts its cardioprotective effect during sustained ischemia but not the PC
stage [36].
Since pertussis toxin pretreatment blocked the protective effect of PC [37], it was
suggested that the A1 adenosine receptor coupled to the G-protein system is a key player in
inducing cardioprotection by PC.

Other receptors including muscarinic M2 [38],

adrenergic α1 [39], and bradykinin B2 [40] are also coupled to the G-protein system and
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were shown to activate PKC and mimic the effect of ischemic PC [41]. A1 adenosine
receptor-G protein- coupling activates phospholipase C which degrades phospholipids of
the membrane to DAG. As a result, DAG activates PKC and causes its translocation from
the cytosol to the membrane by the microtubules [42]. In deed, blocking this activity with
colchicine abolished the effect of ischemic PC, demonstrating the importance of PKC
translocation in PC [35]. Other studies also showed that it is not essential for PKC to be
continuously activated in order to cause cardioprotection by PC; however, the
phosphorylation of certain downstream proteins by PKC prior to sustained ischemia is
necessary for achieving an infarct-sparing effect with PC.

ATP-sensitive potassium channels (KATP channels)
Research involving ATP-sensitive potassium channels (KATP channels) has a
longer history than studies on ischemic preconditioning, since their existence in the
myocardium was first reported in 1983 [43].
The KATP channel exists in the membrane and is modulated by Mg and ATP [44]. KATP
channels were first identified by cardiovascular physiology studies as causing vascular
smooth muscle relaxation in either large or small arteries or as having a negative inotropic
effect on cardiac myocytes [45]. In addition, activation of these channels seems to occur
as a response to decreased intracellular ATP levels, which is normally achieved within a
few minutes after the onset of ischemia. Because KATP channels act as an inward rectifier
[44] when activated, these effects could be caused by an increase of the depolarization
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threshold that reduces excitation of either vascular smooth muscle or cardiac myocytes
followed by vasodilation and shortening of the action potential duration, respectively,
which finally lead to intracellular Ca2+ unloading [45] and, as a result, reduced metabolic
demand. Since these phenomena resemble the acute cardiac responses and cardioprotection
afforded by ischemic preconditioning, it has been postulated that KATP channels might be
one of the critical effectors of both ischemic and pharmacological preconditioning [46].
Pharmacological preconditioning with KATP channel openers was first demonstrated in
1992 [47], and it was thought to be an intervention downstream of the A1 adenosine
receptor [48].
An early study in 1991 [49] demonstrated that not only the cell membrane but also the
inner mitochondrial membrane possessed ATP-sensitive inward rectifier activity, and
therefore suggested the existence of "mitochondrial KATP channels" as opposed to
"sarcolemmal KATP channels". After a long conception that both Ca2+ unloading and
preservation of ATP were related to sarcolemmal KATP channels, it was found that both
processes are actually mediated by mitochondrial KATP channels [50]. As a result,
numerous studies on the cardioprotective effect of mitoKATP channel opening have been
conducted, including many from our laboratory demonstrating the role of mitoKATP
channel-opening in acute as well as delayed PC using several pharmacological agents.
Unfortunately, despite all the positive results of PC associated with the opening of these
channels, these so called "mitochondrial KATP channels" have still not been cloned after
more than 10 years of investigation in spite of dramatic progress in the cloning of many
mitochondrial proteins. Additionally, although some in vitro studies have shown a potent
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effect of putative modulators of mitochondrial KATP channels [51] (diazoxide as an
opener of KATP channels and 5-hydroxydecanoate (5-HD) as an inhibitor which are
almost the only tools available to test the function of these channels), both drugs also have
other important direct effects on cellular respiratory metabolism. Some recent studies using
other models have failed to show complete modulation of the cardioprotective effect of
ischemic preconditioning by these two drugs [52 and 53]. However, Pain et al. [54] have
reported that reactive oxygen species (ROS), which are transiently generated by opening of
the mitochondrial KATP channels, activate downstream cascades that confer
cardioprotection. It is not clear why these differences exist, but some investigators
focusing on mitochondrial KATP channels have suggested that the contribution of
sarcolemmal KATP channels to cardioprotection may be more important in the beating
hearts and less important under nonbeating experimental conditions (i.e., in vitro).
Although many ongoing studies are providing some possible features or characteristics of
mitochondrial KATP channels, the actual cardioprotective role of these channels needs to
be investigated further in order to establish the cause-and-effect relationship between
mitoKATP channel-opening and cardioprotection with PC.

p38MAPK or PI3-K and their downstream cascades
There are over 1500 protein kinases identified so far among all different subclasses.
Their main function is to transfer a terminal phosphate group from ATP or GTP to an
amino acid (AA) residue; serine, threonine, or tyrosine. Different groups involve protein
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kinases that specifically phosphorylate serine or threonine, referred to as ser/thr protein
kinases, or tyrosine protein kinases that would specifically phosphorylate tyrosine. Another
group of protein kinases that phosphorylates all 3 AA’s is a family known as mitogen
activated protein kinases (MAPK). This family is yet the least understood. The major role
that these protein kinases play is intracellular. When cells receive external signals initiated
by several factors such as growth factors, cytokines, pharmacological agents or stress,
intracellular pathways are activated which rapidly alter patterns of gene expression. This is
the essence of cell signaling and the resulting cellular response to various types of stimuli.
A certain extracellular stimulus would potentially activate a specific receptor at the level of
the plasma membrane leading to the generation of second messengers within the cell.
These chemicals and the extent to which they are expressed may alter the activity of
certain protein kinases thus affecting the phosphorylation states of intracellular proteins
and ultimately regulating their function. All these changes caused by the various signaling
pathways eventually lead to specific physiological responses.
Currently, there are four MAP kinase cascades that are differentially activated depending
on stimulus type: the extracellular signal-regulated kinase/mitogen-activated protein kinase
(ERK/MAPK) 1/2 pathway, the c-Jun amino-terminal kinase/stress-activated protein
kinase (JNK/SAPK) pathway, the p38 pathway and the big mitogen-activated protein
kinase BMK/ERK 5 pathway. Activation of the MAP kinase pathways leads ultimately to
the phosphorylation of transcription factors bound to their regulatory elements in the
promoters of target genes. Phosphorylation of these transcription factors is crucial for gene
activation. The use of relatively specific MAP kinase and other inhibitors has allowed
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elaborate investigation of the signaling pathways and/or mechanisms involved in
phosphorylation of certain proteins in response to specific stimuli. The p38 pathway is
inhibited by SB203580, which specifically binds to and inhibits p38 MAP kinase itself,
rather than inhibiting its activation as in the case of some other MAPK’s.
Within the past decade, it was proposed and demonstrated that several cellular stresses
activated the p38 MAPK pathway. At least four isoforms of p38 were shown to exist, they
are termed p38α, β, γ, and δ. There are also several protein kinases downstream of p38 that
are activated following its phosphorylation. The role of p38 MAPK signaling in cellular
responses is diverse, and has in fact given rise to controversy concerning its role in
preconditioning of the myocardium depending on several factors such as cell type and
stimulus.
Despite the controversy concerning the physiological significance of p38 MAP kinase in
the heart, it has been demonstrated that p38 is stimulated by I/R. Recent studies suggest
that increased phosphorylation of p38 MAPK occurred in the preconditioned heart, which
was completely abolished by SB203580, a selective inhibitor of p38 MAPK. It has also
been demonstrated that increased p38 phosphorylation plays a pivotal role in several
cardiac preconditioning approaches whether physiological or pharmacological in nature.
As a result, the role of mitogen-activated protein kinases (MAPKs), which form part of the
second messenger systems that mediate extracellular stimuli, in the cardioprotective effect
of ischemic preconditioning has been further studied.
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Not too long ago, a study in rabbits reported that ischemic preconditioning caused an
increase of p38MAPK activation during sustained ischemia which was correlated with the
cardioprotection provided by preconditioning [55]. However, p38MAPK was not activated
during ischemia in the control group, while contradictory results were obtained a few years
later by in vivo [56] and in vitro [57] studies that suggested p38MAPK activation could in
fact promote ischemic damage. Treatment with anisomycin, a potent p38MAPK (and JNK)
activator, just before ischemia could attenuate ischemic injury, with only the first peak of
p38MAPK activation persisting and the second being abolished. This observation led to
the hypothesis that p38MAPK activation has opposing effects; i.e., transient activation
prevents ischemic injury, whereas continuous activation intensifies it.
Furthermore, MAPKAPK-2 and HSP27 (one of the small heat shock proteins that acts as a
molecular chaperone), which are downstream of p38MAPK, are activated in the
preconditioned myocardium at the onset of sustained ischemia. Interestingly, MAPKAPK2 subsequently activates Akt, which lies downstream of PI3-K [58], to antagonize
apoptotic signals. PI3-K can be activated by PC [59] and is also reported to cause an
increase of nitric oxide (NO) production and the downstream activation of PKC [59]. On
the other hand, HSP27 binds to the z-bands of myofibrils to prevent ischemic degradation
of myofilaments [60] or prevents the interaction of Apaf-1 with procaspase-9 through
binding with cytochrome c [61] which is released from the mitochondria and enhances this
interaction [62].
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Bradykinin and opioids
Several studies have implicated bradykinin [63] as a candidate trigger for
preconditioning. The cardioprotective effect of bradykinin has been intensively
investigated [64], and it is known that preconditioned hearts show an increase of the
interstitial bradykinin level [65]. The downstream effectors are reported to be an increase
of nitric oxide production [66] or opening of KATP channels [67] after activation of the
bradykinin B2 receptor.
While bradykinin is considered to be an endogenous trigger of preconditioning, as
mentioned above, activation of the δ-opioid receptor by opioid peptides has also been
investigated as a potent exogenous trigger of preconditioning in isolated human cardiac
tissue [68]. Many reports have suggested that KATP channels are the downstream
mechanism of cardioprotection, but the relative contribution of either sarcolemmal [69] or
mitochondrial [70] KATP channels to the triggering phase remains unclear. It has also
been shown that by selectively activating the δ-opioid receptor with DPDPE, a selective
agonist, the survival time in mice increased under hypoxic environments. Gross et al also
demonstrated that ischemic PC is mediated by activation of the δ-opioid receptor, and by
employing BNTX, the δ-opioid receptor antagonist, the infarct-limiting effect of PC was
abolished.
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4. Late phase PC: Cellular mechanisms
The late phase of preconditioning, which was initially reported as the "second window of
preconditioning" [12 and 13] in 1993, occurs about 24 hr (the actual time varies among
species and experimental models) after transient preconditioning and lasts for much longer
than the early phase, up to 72 hr post PC.
As previously described, the late phase of ischemic preconditioning has essentially
different signaling mechanisms from the early phase (classical ischemic preconditioning)
such that it involves processes that require a longer time to occur. Recent studies have
revealed that these two types of preconditioning share some triggering mechanisms, while
certain mediators and effectors are reported to be specific for the late phase of
preconditioning. In this part of our discussion, we will focus on the various mediators or
effectors involved in late preconditioning.
Adenosine
The adenosine-triggered cardioprotection that appears after 24 to 72 h is reported to
have some unique characteristics [14]. Adenosine-triggered cardioprotection involves both
adenosine A1 and A3 receptors, and it only reduces the infarct size rather than having an
influence on stunning or arrhythmias. Initial transient activation of adenosine A1 receptors
causes activation of subcellular signaling pathways, such as p38MAPK or HSP27 [71], and
increases the synthesis of manganese superoxide dismutase (Mn–SOD) [72], but the role of
A3 receptors remains not fully understood.
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Nitric oxide (NO)
Nitric oxide (NO) was first identified as endothelium-derived relaxation factor
(EDRF). In the cardiovascular system, it was shown to quite a similar role to adenosine
such as having negative inotropic effects, vasodilatory effects, and inhibition of cytokine
production as well as platelet aggregation. All of these actions are mediated through cyclic
GMP as a second messenger [73]. It has also been suggested that an increase of NO prior
to sustained ischemia plays a part in either ischemic or pharmacological preconditioning
[74], indicating that NO could act as either a trigger or an effector of preconditioning
which also resembles the role of adenosine. Furthermore, in contrast with the established
role of NO in the triggering of late phase cardioprotection, whether NO can trigger the
early phase of cardioprotection remains controversial. NO is reported to share downstream
pathways with various other triggers [such as acetylcholine (Ach), bradykinin, opioids, and
phenylephrine), involving PKC, KATP channels, and the generation of reactive oxygen
species (ROS) in the triggering phase, but its other downstream effects are unknown. Some
studies [73] reported that PKC activates NF-кB after several hours which then causes
increased expression of inducible NO synthase (iNOS) after 4 to 8 h.
Although we have mentioned a direct cardioprotective effect of NO, it also forms
peroxynitrite (ONOO−) and promptly loses its bioactivity as a stimulator of cyclic GMP in
the presence of high levels of free radicals. It remains unclear whether peroxynitrite is
beneficial or harmful to the myocardium because it has been reported to damage vascular
endothelial cells [75], whereas another study showed that formation of ONOO− is required
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for NO to act as a trigger of preconditioning [76]. So, in this respect, it is believed that the
levels of NO produced are critical in terms of NO being harmful or beneficial. NO, in large
amounts, is highly toxic for cells and eventually causes cell death. On the other hand, if
“optimal” concentrations of NO were produced at the right time, NO would activate GC
and lead to the formation of cGMP which in turn activates PKG and results in
cardioprotection through opening of mitoKATP channels. In addition, accumulation of
cGMP, especially in vascular smooth muscle cells, causes smooth muscle relaxation and
hence vasodilation. This vasodilatory effect is believed to potentially cause the release of
certain endogenous mediators of PC, such as adenosine, bradykinin and acetylcholine.
Furthermore, some studies using mice with gene targeting have indicated that endothelial
NOS (eNOS) is also responsible for cardioprotection [79]. Again, regardless what the
source of NO is, whether it is nNOS, iNOS or eNOS, it could probably be concluded that
the overall effect of NO, under optimal doses, on the cardiovascular system is beneficial,
although the results might vary among species and experimental models.

Heat shock proteins (HSPs)
Intensive research has been conducted to examine the role of HSPs in the
cardioprotection induced by ischemic PC. It has been reported that the expression of
HSP70/72, a high molecular weight heat shock protein, peaks at 24 to 48 h after
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preconditioning ischemia [78]. The main known fuction of HSP 70/72 is its action as a
molecular chaperone; however, its cardioprotective effect may be related to other factors
induced by HSPs as previously described for HSP27. Inhibition of PKC, by chelerythrine,
prior to preconditioning completely abrogated the induction of these HSPs [79], suggesting
that PKC also mediates cardioprotection through the generation of HSPs.
On the other hand, ischemic preconditioning also activates Mn–SOD, and the peak level is
seen at 24 h after preconditioning [79]. Because increased expression of Mn–SOD has
been detected in a model of HSP72 overexpression [78], it may also be sequentially
involved in ischemic or heat stress-induced preconditioning. As a result, some studies were
performed to test the effect of exogenous Mn–SOD [80], and they showed that this
approach fails to protect the myocardium against ischemic damage or reperfusion injury.
This suggests that free radicals may play different roles during the process of ischemia and
reperfusion injury depending on the site of their generation, i.e., inside or outside cardiac
myocytes.

Arachidonic acid
The most recent studies on the downstream pathways have addressed
cardioprotection mediated by the induction of enzymes in the arachidonic acid cascade,
mainly cyclooxygenase-2 (COX-2) [81]. iNOS and its product NO may activate COX-2 in
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the late phase of cardioprotection [82], but the contribution of its products is currently
unknown. These findings are interesting with respect to possible links with further
downstream internal mediators that are believed to be the final effectors of
preconditioning, as well as the concept that the immune response may be a direct effector
of the cardioprotection afforded by preconditioning, and are also encouraging with regard
to clinical application.
All the aforementioned mediators of PC are summarized in Figure 1 to illustrate their
interaction at the subcellular level in order to bring about the whole concept of myocardial
PC.
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Figure 1
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5. Pharmacological PC
After having discussed many of the mechanisms identified thus far in ischemic PC,
and after mentioning more than once that inducing brief episodes of ischemia is not a
practical approach for management of patients with cardiovascular disease, we finally
reach the major goal behind all these studies. Scientists in this field always desired to
devise or discover chemicals or pharmacological agents that are able to target one or more
of the signaling molecules implicated in ischemic PC in order to achieve similar
cardioprotective results bypassing the ischemic stimulus. So far, among the many
candidates suggested by experimental studies, there are two agents that have also been
shown to minimize damage due to reperfusion injury in the clinical setting: adenosine and
the KATP channel opener nicorandil.

Adenosine
In a clinical trial [83], patients with acute anterior myocardial infarction who
underwent continuous intravenous infusion of adenosine together with PTCR had smaller
infarcts and better functional recovery than those without adenosine infusion. In this study;
however, no cardiac function data were correlate with the observed reduction in infarct
size. Therefore, more studies should be conducted in order to better evaluate the effect of
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adenosine or ATP administration in the clinical setting not only on infarct size reduction,
but also functional recovery by employing angiography.

KATP channel openers
Some experimental [84] and clinical trials using either intravenous [85] or
intracoronary [86] administration have shown that the no-reflow phenomenon following
reperfusion can be prevented after successful PTCA, together with a reduced infarct size
and better recovery from hypokinesis, by continuous infusion of a KATP channel opener
(nicorandil) just after the procedure. Eventhough the no-reflow phenomenon has been
proposed to be caused by arterial vasospasm [104], the exact mechanism by which
nicorandil improves it remains unclear. Furthermore, the component of the KATP channel
(mitochondrial or sarcolemmal) involved in this action of nicorandil is also controversial
because many reports have confirmed that nicorandil has a stronger effect (10- to 100-fold)
on the mitochondrial KATP channel than on the sarcolemmal KATP channel in vitro [87].
Over the past 30 years, enormous progress has been made in our understanding of the basic
biochemical and molecular mechanisms that underlie the development of lethal ischemiareperfusion injury and the protective actions of therapeutic interventions.

While

adenosine is known to cause preconditioning and protection of the heart under these
circumstances, it has been determined that the clinical effects are not as promising as those
initially reported by experimental studies. Over 3 years ago, we undertook a series of
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novel investigations to determine the role of phosphodiesterase-5 (PDE-5) inhibitors in
cardioprotection.These drugs are a novel class of vasoactive agents that have been
developed for treatment of erectile dysfunction in men. Their mechanism of action
involves active inhibition of PDE-5 enzyme resulting in accumulation of guanosine
monophosphate (cGMP) levels and smooth muscle relaxation in the penis. Our initial
hypothesis was that the vasodilatory action of these drugs may cause the release of certain
endogenous compounds implicated in PC, such as adenosine, bradykinin, or acetylcholine.
These mediators could potentially trigger signaling pathways leading to cardioprotection.
Based on the intriguing hypothesis, we designed and performed the following
investigations:
Aim #1) to investigate whether sildenafil could confer cardioprotection against I/R injury
in a manner similar to ischemic PC in the rabbit model of regional myocardial infarction;
Aim #2) to demonstrate the behaviour of PKC isozymes after sildenafil treatment and their
respective roles in cardioprotection with sildenafil in an in vivo rabbit model;
Aim #3) To show that sildenafil could confer PC-like effects not only in the adult rabbit
model, but also in infant rabbits;
Aim #4) to examine the role of iNOS/eNOS proteins in the infarct-limiting effect of
sildenafil in a mouse model of global I/R;
Aim #5) to elucidate the signaling pathways involving activation of p38/ERK with
sildenafil in an isolated mouse heart model;
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Aim #6) to test the hypothesis that the adenosine A1 receptor plays a role in
cardioprotection with sildenafil using A1 receptor knock-out mice.

Aims 1 to 4 represent published papers in peer reviewed journals. The work on Aims 5 and
6 has been completed and will be submitted for publication in the near future.

CHAPTER 2

Sildenafil (Viagra) induces powerful cardioprotective effect via opening of
mitochondrial KATP channels in rabbits

RAMZI OCKAILI*, FADI SALLOUM*, JOHN HAWKINS AND
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Medical College of Virginia
Virginia Commonwealth University
Richmond, VA 23298, USA
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Summary: Sildenafil citrate (Viagra) is the pharmacologic agent used for treatment of
erectile dysfunction in men. Since this drug has vasodilatory effect, we hypothesized that
such an action may induce preconditioning-like cardioprotective effect via opening of
mitoKATP channels. Rabbits were treated with sildenafil citrate (0.7 mg/kg, iv) either 30
min (acute phase) or 24 hrs (delayed phase) prior to 30 min of ischemia and 3 hrs of
27
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reperfusion. MitoKATP channel blocker, 5-hydroxydecanoate (5-HD, 5 mg/kg, iv) was
given 10 min before ischemia/reperfusion. Infarct size was measured by tetrazolium
staining.

Sildenafil caused reduction in arterial blood pressure within 2 minutes of

treatment, which returned to nearly baseline levels 3 minutes later. The infarct size (% of
risk area, mean±SE) reduced from 33.8±1.7 in control rabbits to 10.8±0.9 during acute
phase (68% reduction, p< 0.05) and 19.9±2.0 during delayed phase (41% reduction, p<
0.05). Similar acute and delayed cardioprotective effect was observed when sildenafil was
administered orally. Systemic hemodynamics also decreased after oral administration of
the drug. However, these changes were mild and occurred slowly. 5-HD abolished
protection with increase in infarct size to 35.6±0.4 and 36.8± 1.6 during acute and delayed
phase respectively (p<0.05). For the first time, we demonstrate that sildenafil induces
acute and delayed protective effect against ischemia/reperfusion injury which is mediated
by opening of mitoKATP channels.

Keywords: KATP channel, viagra, ischemia/reperfusion, infarction

INTRODUCTION
Sildenafil citrate (Viagra) is the first oral agent approved for treatment of erectile
dysfunction in men (5,11). It is a selective inhibitor of phosphodiesterase-5 (PDE-5), an
enzyme that catalyzes the breakdown of a potent smooth muscle relaxing agent cyclic
guanosine monophosphate (cGMP). Sildenfil has been shown to enhance nitric oxide
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(NO)-driven cGMP accumulation in the corpus cavernosum of rabbits without affecting
cAMP formation. In the absence of NO drive, sildenafil had no functional effect on the
human and rabbit isolated corpus cavernosum, but potentiated the relaxant effects of NO
on these tissues (20). Also, it has been shown that sildenafil causes mild to moderate
decreases in systolic and diastolic pressure because of the inhibition of PDE-5 in smooth
muscles in the vascular bed (12). In the present studies, we hypothesized that such a mild
vasodilatory effect of the sildenafil in coronary vasculature could potentially release agents
such as adenosine, bradykinin or NO that may trigger preconditioning-like effect in the
heart.

Since opening of the mitochondrial KATP (mitoKATP) channel mediates the

cardioprotective effect of preconditioning induced by adenosine (1,2,4,6) or sublethal
ischemia (3), we further hypothesized that these channels could potentially be involved in
the cardioprotective effect of sildenafil. Accordingly, the goals of the present study were:
(a) to show that the sildenafil induces both acute and delayed protection against
ischemia/reperfusion injury in vivo and (b) to demonstrate if the protective effect of this
drug is blocked by 5-hydroxydecanoate (5-HD), a selective blocker of mitoKATP channel
(14). Using our in situ rabbit model of myocardial infarction, for the first time, we
demonstrate that sildenafil induced both acute and delayed cardioprotective effects, which
is dependent on the opening of mitoKATP channel.
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MATERIALS AND METHODS
Animals

Male New Zealand White rabbits (2.8 to 3.3 kg) were used for the studies. The care and
use of the animals were conducted in accordance with the guidelines of the Committee on
Animals of Virginia Commonwealth University and the National Institute of Health (NIH)
“Guide for the Care and Use of Laboratory Animals” [DHHS Publication No. (NIH) 8023, Revised, Office of Science and Health Reports, Bethesda, MD 20205].

Surgical procedure: Infarction protocol

The rabbits were anesthesized with an intramuscular injection of ketamine HCl (35 mg/kg)
and xylazine (5 mg/kg). Subsequent doses of ketamine-xylazine (10 mg/kg and 2 mg/kg,
respectively) were administered during the experiment as needed to maintain surgical
anesthesia. Atropine was administered along with the anesthetic in order to keep the heart
rate elevated especially during the surgery protocol. The body temperature was monitored
and maintained at 38°C throughout the experimental protocol. The neck was opened with
a ventral midline incision and tracheotomy performed followed by intubation. The animal
was then mechanically ventilated on a positive pressure ventilator using compressed room
air at 30-35 cycles/min with a tidal volume of approximately 15 ml. Ventilator setting and
pO2 were adjusted as needed to maintain the arterial blood gas parameters within the
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physiological range. The blood gases and pH were measured 12 times for all the groups
during the infarction protocol. The arterial blood gases and pH values ranged between 7.20
and 7.50 with pCO2 maintained between 20 and 50 mmHg and the HCO3 level ranging
between 15.0 and 28.0 mg/L. The pO2 ranged between 60 and 150 mmHg with the
saturation constantly kept above 90%.

The jugular vein was cannulated with a

polyethylene (PE) catheter for continuous infusion of 0.9 % saline solution. The carotid
artery likewise was dissected and cannulated with a PE catheter for blood sampling and
continuous arterial pressure monitoring.

Electrocardiographic leads were attached to

subcutaneous electrodes to monitor either limb lead II or lead III.
Following stabilization of the hemodynamics, a left thoracotomy was performed through
the fourth intercostal space and the pericardium opened to expose the heart. A 5-0 silk
suture with atraumatic needle was then passed around the left anterior descending artery
(LAD) midway between the atrioventricular groove and the apex. The ends of the tie were
then threaded through a small vinyl tube to form a snare. To induce infarction, the LAD
was occluded for 30 min by pulling the snare and then fixing it in place by clamping the
vinyl tube with a hemostat. A bolus of heparin sodium 500 IU was given immediately
before coronary occlusion for prophylaxis against thrombus formation around the snare.
Myocardial ischemia was confirmed visually in situ by regional cyanosis, ST
elevation/depression or T wave inversion on electrocardiogram, hypokinetic/dyskinetic
movement of the myocardium, and relative hypotension. After 30 min of ischemia, the
snare was released and the heart was allowed to reperfuse for 180 min. This was readily
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confirmed by hyperemia over the surface of the previously ischemic-cyanotic segment. The
thoracic cavity was covered with the saline-soaked gauze to prevent the heart from drying.

Measurement of Infarct Size

Following completion of ischemia/reperfusion protocol, 500 units of heparin was injected
and the heart was removed quickly and mounted on a Langendorff apparatus.

The

coronary arteries were perfused with 0.9% saline containing 2.5 mM CaCl2. After the
blood was washed out, the ligation around the coronary artery was re-tightened and
approximately 2 ml of 10 % Evan’s blue dye injected as a bolus into the aorta until most of
the heart turned blue. The hearts were then perfused with saline to washout the excess
Evan’s blue, removed from the Langendorff apparatus, frozen and cut into 4 to 6 transverse
slices from apex to base of equal thickness (≈1 mm). The slices were then incubated in 1
% TTC solution in isotonic pH 7.4 phosphate buffer at 370C for 20 minutes. TTC reacts
with NADH in the presence of dehydrogenase enzymes causing the cells viable to stain
with a deep red color. Red-stained viable tissue was easily distinguished from the infarcted
gray or white-unstained necrotic tissue. The slices were subsequently fixed in 10 %
formalin solution. The area at risk was determined by negative staining with Evan’s blue.
The areas of infarcted tissue, the risk zone, and the whole left ventricle (LV) were
measured by computer morphometry using a Bioquant imaging software (BIO98). Infarct
size was expressed both as a percentage of the ischemic risk area.
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Measurement of hemodynamics

Hemodynamic measurements included heart rate and mean arterial pressure, systolic and
diastolic blood pressure. Rate-pressure product was calculated as the product of heart rate
and peak arterial pressure.

Study Protocol

All animals were subjected to infarction protocol consisting of 30 minutes of sustained
ischemia by occlusion of coronary artery followed by 180 minutes of reperfusion. The
effect of sildenafil was studied in the absence or presence of 5-HD in two phases i.e., the
acute and delayed phase. In the acute phase, myocardial infarction protocol was carried out
30 min after treatment with sildenafil. In the delayed phase, ischemia/reperfusion protocol
was carried out 24 hours later. The rabbits were randomly assigned into one of the
following groups. Following is the description of the experimental groups:

Group I: (saline control, n=10): Rabbits received 0.9 % saline; Group II: (Sildenafil,
acute phase, n=6): The Viagra tablets were crushed and 0.7 mg/kg sildenafil was
dissolved in 3 ml saline. This preparation was given as IV bolus, approximating on a
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mg/kg basis, the clinical dose of 50 mg administered to a 70 kg patient as described by
Przyklenk and Kloner (15).

The animals were subjected to ischemia/reperfusion 30

minutes later. Group III: (Sildenafil, delayed phase, n=6). Animals were treated with
sildenafil as in group II and subjected to ischemia/reperfusion 24 hrs later; Group IV:
(5HD, n=7). Control rabbits treated with 5-HD (5 mg/kg, IV) 10 min prior to sustained
ischemia and reperfusion; Group V: (Sildenafil, + 5HD, acute phase, n=6 ). Sildenafil
treated rabbits as in group II were given 5-HD (5 mg/kg, IV) 10 min prior to ischemia and
reperfusion; Group VI: (Sildenafil, + 5HD, delayed phase, n=6). Sildenafil treated
rabbits as in group III were given 5-HD (5 mg/kg, IV) 10 min prior to ischemia and
reperfusion.

In addition, a subset of three groups of animals (n=5-6 per group) were given sildenafil
citrate orally (1.4 mg/kg) or saline (control) in order to determine the early and delayed
cardioprotective effect of the drug through this route. Since there is 40 % bioavailability of
sildenafil citrate after oral administration (http://www.pfizer.com/hml/pi's/viagrapi.pdf),
we used double the dose of intravenous route i.e., 1.4 mg/kg which is equivalent to clinical
dose of 100 mg for a 70 kg patient.

Statistics

All measurements of infarct size and risk areas are expressed as group means ± SEM.
Changes in hemodynamics and infarct size variables were analyzed by a two-way repeated
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measure ANOVA to determine the main effect of time, group and time by group
interaction. If the global tests showed major interactions, post hoc contrasts between
different time-points within the same group or between different groups were performed
using t- test. Statistical differences were considered significant if p value was less than
0.05.

RESULTS

Hemodynamics: Intravenous administration of sildenafil citrate (0.7 mg/kg) caused rapid
decrease in hemodynamcs as indicated by 24.5 %, 47.3 % and 38.8 % decline in systolic,
diastolic and mean arterial pressure respectively within 2 minutes (Figure 1A).

The

systemic hemodynamics returned to nearly baseline levels by 5 minutes after treatment
with sildenafil. No significant changes in heart rate were observed following treatment
with sildenafil (not shown).

The effect of orally administered sildenafil citrate on

systemic hemodynamics was milder and slower as compared to the intravenous dose of the
drug.

The orally administered sildenafil caused approximately 9.2 %, 12.5 % and 10.3 %

decrease in systolic, diastolic and mean arterial pressure respectively after 30 minutes of
treatment with the drug (Figure 1B). This hypotensive response remained significant even
at 60 minutes after oral administration of drug. No changes in heart rate were observed.
Also, no significant changes in systemic hemodynamics were observed in control animals
given saline orally (data not shown).
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The heart rate, mean arterial pressure and rate pressure product during baseline,
preischemia, 30 min of ischemia and 180 min of reperfusion period are shown in Table 1
and 2. The hemodynamics remained reasonably stable, although they gradually decreased
in all the groups during experimental protocol. Except at the indicated time points, the
mean values were not significantly different between the groups at any time point.

Infarct size

The infarct size (% of risk area) reduced from 33.8 ± 1.7 in the saline treated control group
to 10.8 ± 0.9 during acute phase (68 % reduction, mean±SE, p< 0.05) and 19.9 ± 2.0
during delayed phase (41 % reduction) in the sildenafil-treated rabbits (Figure 2A). A
similar reduction in infarct size was observed acutely (after 60 min) and 24 hrs later when
sildenafil was administered orally (Figure B). The infarct-limiting effect of sildenafil was
abolished in animals treated with 5-HD as shown by significant increase in infarct size to
35.6 ± 0.4 during acute phase and 36.8± 1.6 in the delayed phase (p<0.05 versus groups II
and III treated with sildenafil, Figure 2A). Control animals treated with 5-HD had an
infarct size of 33.5 ± 1.9 which was not different from infarct size of 33.8 ± 1.7 in the
saline controls (P>0.05). A similar trend in the changes in infarct size was observed when
expressed as a percentage of the left ventricle (not shown). Similarly, the risk areas
expressed as percentage of left ventricle were not statistically significant different between
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the groups. These data suggest that changes in the infarct size observed among various
groups were not related to the percentage of the area of the left ventricle that was occluded
by our technique.

Representative sections of the heart treated with sildenafil citrate

intravenously clearly demonstrated significantly larger area of viable tissue (brick red
color) as compared to saline treated control and sildenafil+5-HD treated animals, which
had much larger gray and white areas in the risk zone (Figure 3).

DISCUSSION

Sildenafil citrate (Viagra) is currently the only approved oral drug for treatment of erectile
dysfunction in men. However, little is known about other beneficial effects of this drug.
We report here our novel observation about the preconditioning-like effect of sildenafil in
the adult rabbit heart.

Our results show that intravenous administration of sildenafil

induces acute (early) and delayed cardioprotective effect as indicated by significant
reduction in the infarct size when compared to the saline-treated controls. Since the drug is
taken orally by patients, we further showed that feeding the rabbits with sildenafil citrate
reduced infarct size acutely (after 1 hr) as well as 24 hrs later which was comparable to the
infarct size reduction obtained by intraveous administration of the drug. The selective
blocker of mitoKATP channels, 5-HD, when administered before the ischemia/reperfusion
protocol, abolished both the early as well as delayed cardioprotection induced by sildenafil
citrate. Intravenous administration of sildenafil citrate caused severe transient decrease in
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the systemic hemodynamics (diastolic, systolic and mean arterial blood pressure) within 2
minutes after treatment returned to nearly baseline levels after 3 minutes. Although a
significant decrease in systemic hemodynamics was also observed after oral administration
of the drug, these changes were mild and occurred slowly. The hemodynamics remained
largely unchanged among the groups during ischemia/reperfusion protocol.

To our

knowledge, this is the first study demonstrating (a) the direct cardioprotective effect of
sildenafil in vivo and (b) the involvement of mitoKATP channel in mediating this protection
in the ischemic heart.

Sildenafil is a potent selective inhibitor of PDE-5 in vascular smooth muscle cells which is
known to enhance erectile function in men (20). Sexual stimulation results in the release
of NO from nerves and endothelial cells in the corpus cavernosum of the penis that
stimulates guanylate cyclase with subsequent formation of cGMP.

Accumulation of

cGMP leads to smooth muscle cell relaxation in the arteries, arterioles and sinusoids in the
corpus cavernosum that allow this erectile tissue to fill with blood and causing erection
(10). Men with erectile dysfunction may be unable to produce adequate amounts of cGMP
because it may be broken down by PDE-5, which is found in high levels in the genitalia.
Sildenafil inhibits PDE-5 allowing an increase in cGMP and improving vasodilation.
Besides genitalia, PDE-5 is found in other vascular and visceral smooth muscles also (21).
As a result, the administration of sildenafil causes vasodilation and decrease in the blood
pressure. We hypothesized that such a vasodilatory action of sildenafil could potentially
release endogenous mediators of preconditioning such as adenosine, bradykinin or NO.

39
One or more of these mediators may trigger signaling cascade leading to opening of
mitoKATP channel resulting in acute and delayed cardioprotective effect. Indeed our results
show a very impressive acute cardioprotective effect which is comparable or even better
than ischemic preconditioning (28) and pharmacological preconditioning induced by
activation of adenosine receptors, monophosphoryl lipid A or bradykinin (9,13,17,26,27).
The cardioprotective effect after 24 hrs was less pronounced during delayed phase i.e.,
41% reduction in infarct size as compared to 67 % in the acute phase (% risk area),
implying that there may be gradual waning of the sustained protective effect.
Alternatively, it is possible that sildenafil-induced protection is biphasic, with acute and
delayed phase protection controlled by separate mechanisms.

Another interesting observation in the present study is that both acute and delayed
cardioprotective effects were blocked by 5-HD suggesting that opening of mitoKATP
channels play an important role in the infarct size reduction by sildenafil in our model.
Several studies have now conclusively demonstrated that opening of mitoKATP channels
play an important role in ischemic as well as pharmacological preconditioning in the heart
(7,8,18,22). Mitochondria are known to play an essential role in cell survival by ATP
synthesis and maintenance of Ca2+ homeostasis. Opening of the mitoKATP channel partially
compensates the membrane potential, which enables additional protons to be pumped out
to form a H+ electrochemical gradient for both ATP synthesis and Ca2+ transport (16). The
acute protection induced by sildenafil may be mediated by opening of the mitoKATP
channel either directly or through a variety of signaling pathways such as activation of
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protein kinase C and MAP kinases.

The delayed phase could be through the signaling

cascade leading to the synthesis of inducible nitric oxide synthase, generation of NO and
opening of the mitoKATP channels as described previously (19,23,24,29-31). Currently we
do not have the evidence in support of this notion and further investigations are needed to
determine the cellular and molecular mechanisms of cardioprotection by sildenafil.

In the present studies, the sildenafil was given in normal rabbits with no sexual
stimulation. It has been suggested that sexual activity is comparable to moderate exercise,
particularly in men with coronary artery disease who may have been physically inactive to
engage in sexual activity (10). Since exercise triggers preconditioning-like effect in animal
models (25), it is possible that men taking sildenafil prior to sexual intercourse could
potentially have additive cardioprotectve effect of moderate exercise. On the other hand,
concerns over the safe use of sildenafil in patients with ischemic heart disease have been
raised.

While the overall safety of sildenafil use has been well established, the co-

administration of long and short-acting nitrate preparations has been associated with
significant hypotension and adverse cardiovascular effects. In addition, caution has been
recommended in prescribing sildenafil to patients with unstable ischemic coronary
syndromes, severe LV dysfunction, or patients who are on multiple-drug antihypertensive
regimens (5, 12).

Therefore, careful clinical studies are required to evaluate the

preconditioning-like effect of sildenafil in patients with ischemic heart disease.
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In conclusion, for the first time, we have demonstrated that intravenous or oral
admininstration of sildenafil citrate induces significant cardioprotective effect against
ischemia/reperfusion injury, the impact of which was powerful within 30 minutes and
persisted to slightly lesser degree 24 hrs after administration of the drug. The extent of
protection observed with sildenafil was comparable to preconditioning induced by
sublethal ischemia and several other pharmacological agents. Furthermore, our results
show that the cardioprotective effect of sildenafil was mediated by opening of mitoKATP
channel, a proposed end-effector of myocardial preconditioning (8,22).

Further

investigations are needed to understand the molecular mechanism(s) of sildenafil-induced
cardioprotective effect which would help in expanding the utility of this drug for other
cardiovascular diseases in addition to the current use for treatment of erectile dysfunction
in men.

Acknowledgement
This work was supported in part by Grants HL 51045 and HL-59469 from National
Institutes of Health (RCK). John Hawkins was supported by a fellowship from MidAtlantic Consortium of the American Heart Association.

42
REFERENCES
1. Auchampach, J.A. and G.J. Gross. Adenosine A1 receptors, KATP channels, and
ischemic preconditioning in dogs. Am J Physiol 33: H1327-H1336, 1993.
2. Baxter, G.F. and D.M. Yellon. ATP-sensitive K+ channels mediate the delayed
cardioprotective effect of adenosine A1 receptor activation. J Mol Cell
Cardiol 31: 981-989, 1999.
3. Bernardo, N.L., M. D'Angelo, S. Okubo, A. Joy, and R.C. Kukreja. Delayed
ischemic preconditioning is mediated by opening of ATP-sensitive potassium
channels in the rabbit heart. Am J Physiol 276: H1323-H1330, 1999.
4. Bernardo, N.L., S. Okubo, M.M. Maaieh, M.A. Wood, and R.C. Kukreja.
Delayed preconditioning with adenosine is mediated by opening of ATPsensitive K+ channels in rabbit heart. Am J Physiol 277: H128-H135,1999.
5. Cheitlin, M.D., A.M. Hutter, R.G. Brindis, and et al. Use of sildenafil (Viagra) in
patients with cardiovascular disease. J Am Coll Cardiol 33: 273-282, 1999.
6. Cohen, M.V., C.P. Baines, and J.M. Downey. Ischemic preconditioning: from
adenosine receptor to KATP channel. Annu.Rev.Physiol 62: 79-109, 2000.
7. Fryer, R.M., A.K. Hsu, J.T. Eells, H. Nagase, and G.J. Gross. Opioid-induced
second window of cardioprotection: potential role of mitochondrial KATP
channels. Circ Res 99: 846-851, 1999.

43
8. Gross, G.J. and R.M. Fryer. Sarcolemmal versus mitochondrial ATP-sensitive K+
channels and myocardial preconditioning. Circ Res 84: 973-979, 2001.
9. Janin, Y., Y.-Z. Qian, J.B. Hoag, G.T. Elliott, and R.C. Kukreja. Pharmacologic
preconditioning with monophosphoryl lipid A isabolished by 5hydroxydecanoate, a specific inhibitor of the KATP channel. Cardiovasc
Pharmacol 32: 337-342, 1998.
10. Kloner, R.A. Cardiovascular risk and sildenafil. Am J Cardiol 86: 57-61, 2000.
11. Kloner, R.A. and J.P. Jarow. Erectile dysfunction and sildenafil citrate and the
cardiologist. Am J Cardiol 83: 576-582, 1999.
12. Kloner, R.A. and R.M. Zusman. Cardiovascular effects of sildenafil citrate and
recommendationsfor its use. Am J Cardiol 84: 11-17, 1999.
13. Kositprapa, C., R. Ockaili, and R.C. Kukreja. Bradykinin B2 receptor is involved
in the late phase of preconditioning in rabbit heart. J Mol Cell Cardiol 33:
1355-1362, 2001.
14. Liu, Y., N. Sato, B. O'Rourke, and E. Marban. Mitochondrial ATP-dependent
potassium channels: novel effectors of cardioprotection? Circulation 97:
2463-2469, 1998.

44
15. Przyklenk, K. and R.A. Kloner. Sildenafil citrate (Viagra) does not exacerbate
myocardial ischemia in canine models of coronary artery stenosis. J Am Coll
Cardiol 37: 286-292, 2001.
16. Szewczyk, A. The ATP-regulated K+ channel in mitochondria: five years after its
discovery. Acta Biochim Pol 43: 713-719, 1996.
17. Takano, H., R. Bolli, R.G. Black, E. Kodani, X.L. Tang, Z. Yang, S.
Bhattacharya, and J.A. Auchampach. A1 or A3 adenosine receptors induce
late preconditioning against infarction in conscious rabbits by different
mechanisms. Circ Res 88: 520-528, 2001.
18. Takashi, E., Y. Wang, and M. Ashraf. Activation of mitochondrial KATP channel
elicits late preconditioning against myocardial infarction via protein kinase C
signaling pathway. Circ Res 85: 1146-1153, 1999.
19. Tejero-Taldo, M.I., E. Gursoy, T.C. Zhao, and R.C. Kukreja. Alpha-adrenergic
receptor stimulation produces late preconditioning through inducible nitric
oxide synthase in mouse heart. J Mol Cell Cardiol 34: 185-195, 2002.
20. Wallis, R.M. The pharmacology of sildenafil, a novel and selective inhibitor of
phosphodiesterase (PDE) type 5. Nippon Yakurigaku Zasshi 114 (Suppl): 2226, 1999.

45
21. Wallis, R.M., J.D. Corbin, S.H. Francis, and P. Ellis. Tissue distribution of
phosphodiesterase families and the effects of sildenafil on tissue cyclic
nucleotides, platelet function, and the contractile responses of trabeculae
carneae and aortic rings in vitro. Am J Cardiol 83 (Suppl): 3-12, 1999.
22. Wang, Y., M. Kudo, M. Xu, A. Ayub, and M. Asharf. Mitochondrial KATP channel
as an end effector of cardioprotection during late preconditioning: triggering
role of nitric oxide. J Mol Cell Cardiol 33: 2037-2046, 2001.
23. Xi, L., N.C. Jarrett, M.L. Hess, and R.C. Kukreja. Essential role of inducible
nitric oxide synthase in monophosphoryl lipid A-induced late
cardioprotection: evidence from pharmacological inhibition and gene
knockout mice. Circulation 99: 2157-2163, 1999.
24. Xi, L., F. Salloum, D. Tekin, N.C. Jarrett, and R.C. Kukreja. Glycolipid RC-552
induces delayed preconditioning-like effect via iNOS-dependent pathway in
mice. Am J Physiol 277: H2418-H2424,1999.
25. Yamashita, N., G.F. Baxter, and D.M. Yellon. Exercise directly enhances
myocardial tolerance to ischaemia-reperfusion injury in the rat through a
protein kinase C mediated mechanism. Heart 85: 331-336, 2001.
26. Yao, Z., J.A. Auchampach, G.M. Pieper, and G.J. Gross. Cardioprotective effects
of monophosphoryl lipid A, a novel endotoxin analogue, in the dog.
Cardiovasc Res. 27: 832-838, 1993.

46
27. Yoshida, K.I., M.M. Maaieh, J.B. Shipley, M. Doloresco, N.L. Bernardo, Y.Z.
Qian, G.T. Elliott, and R.C. Kukreja. Monophosphoryl lipid A induces
pharmacologic 'preconditioning' in rabbit hearts without concomitant
expression of 70-kDa heat shock protein. Mol.Cell Biochem. 156: 1-8, 1996.
28. Ytrehus, K., Y. Liu, and J.M. Downey. Preconditioning protects the ischemic
rabbit heart by protein kinase C activation. Am J Physiol 266: H1145-H1152,
1994.
29. Zhao, T., L. Xi, J. Chelliah, J.E. Levasseur, and R.C. Kukreja. Inducible nitric
oxide synthase mediates delayed myocardial protection induced by activation
of adenosine A1 receptors: evidence from gene-knockout mice. Circulation
102: 902-907, 2000.
30. Zhao, T.C. and R.C. Kukreja. Late preconditioning elicited by activation of
adenosine A3 receptor in heart: Role of NFkappaB, iNOS and mitochondrial
KATP channel. J Mol Cell Cardiol 34:263-77 2002.
31. Zhao, T.C., M.M. Taher, K.C. Valerie, and R.C. Kukreja. p38 triggers late
preconditioning elicited by anisomycin in heart: Involvement of NF-kappaB
and iNOS. Circ Res I89: 915-922, 2001.

47
Figure Legends

Figure 1:

Changes in hemodynamics following administration of sildenafil

intravenously (A) or orally (B) administration of sildenafil citrate. SBP – systolic
blood pressure, DBP – diastolic blood pressure; MAP – mean arterial blood pressure.
Results are means±SE from 6-7 rabbits.

Figure 2: A. Bar diagram showing infarct size (% risk area) after intravenous
administration of sildenafil citrate. Saline control - Animals receiving 0.9 % saline;
Sildenafil (acute phase) - Rabbits receiving sildenafil (0.7 mg/kg, IV) 30 min prior to
ischemia/reperfusion; Sildenafil (delayed phase): animals receiving sildenafil (0.7 mg/kg,
IV) 24 hrs prior to ischemia/reperfusion. 5-HD – Control (saline-treated) rabbits received
5-HD (5 mg/kg) 10 min prior to sustained ischemia and reperfusion. Sildenafil+5-HD
(acute phase): Sildenafil treated rabbits given 5-HD (5 mg/kg, IV) 10 minutes prior to
sustained ischemia and reperfusion. Sildenafil+5-HD (delayed phase): Rabbits treated
with sildenafil 24 hrs prior to ischemia/reperfusion were given 5-HD.

Results are

means±SEM in 6-7 rabbits in each group. *P < 0.05 compared to control, sildenafil,
sildenafil + 5-HD (acute and delayed), and 5-HD groups.
B. Reduction of infarct size (% of risk area) after oral administration of sildenafil
citrate. Rabbits were given sildenafil (1.4 mg/kg) or equivalent volume of saline prior to
ischemia/reperfusion protocol which was carried out after 60 min (acute phase) and 24 hrs
later (for delayed phase).

48

Figure 3: Representative sections of the heart demonstrating reduction of postischemic infarct size 30 minutes following treatment with sildenafil and blockade of
protective effect with 5-HD.

At the end of experimental protocol as described in

Methods, the hearts were perfused with Evan’s blue to demarcate the risk area. Each heart
was then sliced into 4-5 sections and stained with TTC followed by fixation in formalin.
The blue areas represent normal perfused tissue. The viable areas are stained brick red
whereas infracted are gray or white. Note that significant viable area in the sections of the
heart treated with sildenafil as compared to saline control or salidenafil + 5-HD treated
rabbit. Similar pattern was observed in the sections of the heart from delayed phase groups
(not shown).
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Abstract
Sildenafil citrate (Viagra) is the most widely used drug for treating erectile
dysfunction in men. We recently demonstrated that it induces potent protective effects
against ischemia-reperfusion (I-R) injury in rabbit hearts through opening of mitochondrial
KATP channels.

In the present study, we investigated the role of nitric oxide (NO)-

dependent signaling pathway in delayed cardioprotection by sildenafil. Adult male ICR
mice were treated with Saline or Sildenafil (0.7 mg/kg, i.p.) 24 hours before global I-R in
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Langendorff mode.

Infarct size was reduced from 27.6±3.3% in saline controls to

6.9±1.2% in sildenafil-treated mice (means±SEM, P<0.05) without compromising cardiac
function. RT-PCR revealed a transient increase in endothelial and inducible NO synthases
(eNOS and iNOS) mRNA in sildenafil-treated mice, peaking at 45 min (eNOS) and 2
hours (iNOS) after sildenafil injection. The magnitude of mRNA increase was more
pronounced for iNOS than eNOS. In addition, a significant increase in both iNOS and
eNOS protein was detected 24 hours after sildenafil treatment. Selective inhibitor of
iNOS, 1400W (10 mg/kg, i.p. given 30 min before I-R) abolished sildenafil-induced
protection (23.7±2.8%, P<0.05 vs. Sildenafil). These data suggest that induction of NOS
isoforms is an essential component of signaling mechanism for sildenafil-induced delayed
preconditioning. However, iNOS appears to be the primary isoform that mediates the
robust cardioprotection.

Introduction

Sildenafil citrate (Viagra) is a selective inhibitor of phosphodiesterase-5 (PDE-5) that
catalyzes the breakdown of cGMP – one of the primary factors involved in smooth muscle
relaxation. It enhances nitric oxide (NO)-driven cGMP accumulation which in turn causes
vasodilatation in corpus cavernosum. Sildenafil has become the most widely used drug for
treating erectile dysfunction (ED) in men since its market debut in 1998.1 Interestingly, we
recently discovered a powerful preconditioning-like effect of sildenafil in rabbit hearts.2
Both intravenous and oral administration of sildenafil caused significant reduction of
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infarct size following ischemia/reperfusion.

The protection was abolished by 5-

hydroxydecanoate, a selective blocker of mitoKATP channels.2 However, the mechanism by
which sildenafil triggers signaling cascade leading to opening of mitoKATP remains
speculative2. There is mounting evidence suggesting a role of NO in modulating mitoKATP
.3-6 The synthesis of NO is catalyzed by three isoforms of NO synthase, namely, neuronal
(nNOS), inducible (iNOS), and endothelial (eNOS), among which iNOS has been
identified as the essential mediator of delayed preconditioning induced by divergent
pathophysiological stimuli or pharmacological agents, such as brief episodes of ischemiareperfusion (I-R),7 endotoxin derivatives,8,9 G protein-coupled membrane receptor
agonists,10,11 whole body hyperthermia,12 and systemic hypoxia.13 However, no studies are
available showing any link between sildenafil and activation of NOS-dependent signaling
cascade. The goal of the present report was to show if: 1) sildenafil induces synthesis of
NOS isoforms in the heart and, 2) iNOS mediates the delayed preconditioning effect in the
mouse heart.

Materials and Methods

Physiological Studies. Adult male out-bred ICR mice were supplied by Harlan.
Animal experiment protocols were approved by the Institutional Animal Care and Use
Committee of Virginia Commonwealth University. Viagra pills (Pfizer Inc.) were ground
into powder and dissolved in saline. The drug solution was filtered (0.45 µm pore size)
before intraperitoneal (i.p) injection. iNOS inhibitor – 1400W was obtained from Alexis.
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We used Langendorff isolated perfused mouse heart model subjected to 30 min of global
ischemia and 30 min of reperfusion. Myocardial I-R injury was assessed by measuring
infarct size, contractile function, and coronary flow as described previously.9
Twenty eight mice were randomized into the following four groups (n = 6-9/group): 1)
Saline (0.15 ml, i.p.); 2) Sildenafil (0.7 mg/kg, i.p., equivalent to 50 mg Viagra pill used
for ED patients, given 24 hrs befre I-R); 3) Sildenafil+1400W (10 mg/kg, i.p.,14 given 30
min prior to I-R); and 4) Saline+1400W.

Measurement of NOS isoforms. Mice were treated with sildenafil (0.7 mg/kg, i.p.),
hearts were removed at 15 min, 30 min, 45 min and 1, 2, 3, 4, 24 hrs post injection (n =
3/group). Three non-treated hearts were used as controls. Tissue samples were ground
under liquid nitrogen and homogenized with TRI Reagent (Molecular Research Center) for
extracting total RNA, which was reverse-transcribed into cDNA at 50 oC for 30 min using
OneStep RT-PCR Kit from Qiagen. The oligonucleotide primers were synthesized based
on published sequences for murine iNOS, eNOS, and GAPDH.15 (Integrated DNA
Technology). The RT-PCR products were electrophoresed on 1.5% Tris-Acetate-EDTA
agarose gel. The target bands were identified based on their specific size using DNA
standards.
iNOS and eNOS proteins were measured by Western blots as described previously.13
In brief, triplicate heart samples were collected 24 hours after saline or sildenafil injection
and homogenized in ice-cold RIPA buffer (Upstate Biotechnology). The homogenate was
centrifuged at 10,000g for 10 min under 4°C, and supernatant was recovered as the total
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cellular protein. 60 µg total protein from each sample was separated by SDS/PAGE on
10% acrylamide gels and transferred to a PVDF membrane, and then blocked with 5%
non-fat dry milk in TBS.

The membrane was subsequently incubated with a rabbit

polyclonal antibody (Santa Cruz; dilution 1:500) reacting specifically to iNOS, eNOS, or
actin. The secondary antibody was a horseradish peroxidase-conjugated anti-rabbit IgG
(Amersham, 1:1,000 dilution).

The membranes were developed using enhanced

chemiluminescence and exposed to x-ray film. The mRNA and protein expression were
quantified by scanning each of the RT-PCR or Western blot band using a densitometer
(Bioquant 98).
Data Analysis and Statistics. Data are presented as means±SEM. The difference
among the treatment groups or the time points after sildenafil injection was compared by
unpaired t test or one-way ANOVA followed by Student-Newman-Keuls post-hoc test.
P<0.05 was considered significant.

Results and Discussion
Pretreatment of mice with sildenafil reduced infarct size 24 hrs later (6.9±1.2%), as
compared to saline-treated controls (27.6±3.3%; P<0.05, Figure 1). The infarct-limiting
effect of sildenafil was not associated with compromised ventricular contractile function, i.e.
stunning (Figure 1, Bottom panel), which is in agreement with the results of Przyklenk and
Kloner.16 Sildenafil did not alter pre- or post-ischemic coronary flow (data not shown),
indicating its cardioprotective effect may be independent of its vascular response 24 hrs later.
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These results confirmed our previous findings showing a powerful cardioprotective effect
of sildenafil in rabbit heart.2 There was increase in iNOS and eNOS mRNA and protein
expression (Figure 2 and 3). The levels of these transcripts increased transiently, peaking
at 45 min (eNOS) and 2 hrs (iNOS) after sildenafil treatment and returning to baseline
levels several hours later (Figure 2). The magnitude of increase for iNOS was much higher
compared with eNOS. In addition, sildenafil-induced protection was abolished by selective
iNOS inhibitor, 1400W (Infarct size, 23.7±2.8%, P<0.05 vs. Sildenafil). 1400W had no
significant effect on infarct size as compared with saline-treated hearts (24.5±1.0%; P>0.05
vs. Saline).
Several studies have shown that NO derived from iNOS plays a major role in delayed
cardioprotection induced by endotoxin derivatives,8,9 agonists of adenosine or adrenergic
receptors,10,11 p38 activator,17 and mitoKATP opener – diazoxide.6 The role of sildenafil in
stimulating the release of NO in heart is unknown. We provide the first evidence that
sildenafil is a potent inducer of iNOS mRNA and protein, which leads to delayed
cardioprotection. Although eNOS mRNA and protein also increased, their quantitative
expression was lower than iNOS. The role of eNOS is not clear in the present study. The
complete blockade of cardioprotection with 1400W given before ischemia rules out the
role of eNOS in the mediator phase of delayed protection. However, eNOS may play a
role in the trigger phase, i.e. at the time of sildenafil treatment when NO from eNOS may
initiate the signaling cascade leading to iNOS expression as proposed by Bolli and
coworkers.18,19 The iNOS-catalyzed NO generation could potentially activate guanylate
cyclase resulting in enhanced formation of cGMP. cGMP may activate protein kinase G
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(PKG) that can subsequently open mitochondrial KATP channel resulting in the
cardioprotective effects as recently reported.20
To conclude, for the first time, our results show that sildenafil induces delayed
preconditioning which is primarily mediated by NO derived from iNOS. Further studies
are needed to understand the signaling mechanism(s) that lead to transcription and
expression of eNOS and iNOS in the heart. The current study in a model of global I-R
further expands our knowledge on the cardioprotective effect of sildenafil, which may
potentially be used for treatment of patients with ischemic heart diseases.
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Legend of Figures

Figure 1.

Effect of sildenafil and/or 1400W on myocardial infarct size (Top) and

ventricular functional recovery (Bottom) following global ischemia-reperfusion.

Figure 2. Time course of iNOS and eNOS mRNA expression determined with RTPCR following sildenafil treatment.

Top panel shows representative pictures of 3

independent experiments. The scatter plots present the densitometric results averaged from
3 individual hearts for each time point, which were normalized against GAPDH level for
each sample.

Figure 3. Cardiac expression of iNOS and eNOS protein 24 hrs after sildenafil
treatment.

The bar graph shows the densitometric quantification averaged from 3

individual hearts for each group, which is normalized against Actin level for each sample.
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ABSTRACT

Sildenafil citrate (Viagra) is the most widely used pharmacological drug for
treating erectile dysfunction in men. It has potent cardioprotective effects against ischemiareperfusion (I/R) injury via nitric oxide and opening of mitoKATP channels. We further
investigated the role of protein kinase C (PKC)-dependent signaling pathway in sildenafilinduced cardioprotection. Rabbits were treated (orally) with sildenafil citrate (1.4 mg/kg,
iv) 30 min prior to index ischemia for 30 min and reperfusion for 3 hrs. PKC inhibitor,
chelerythrine (5 mg/kg, iv) was given 5 min prior to sildenafil. Infarct size (% of risk area)
reduced from 33.65 ±2.17 in vehicle (saline) group to 15.07±0.63 in sildenafil-treated
groups, a 45 % reduction compared to the vehicle (mean ± SEM, p<0.05). Chelerythrine
abolished sildenafil-induced protection as demonstrated by increase in infarct size to
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31.14±2.4 (p<0.05). Chelerythrine alone had an infarct size of 33.5±2.5, which was not
significantly different when compared to DMSO treated group (36.8±1.7, P>0.05).
Western blot analysis demonstrated translocation of PKC-α, -θ and -δ isoforms from
cytosol to membrane after treatment with sildenafil. However, no change in PKC-β and -ε
isoforms was observed. These data provide direct evidence of an essential role of PKC,
and potentially PKC-α, -θ and -δ in sildenafil-induced cardioprotection in rabbit heart.

Introduction

Sildenafil Citrate (Viagra), a specific phosphodiesterase-5 (PDE-5) inhibitor
currently approved for the treatment of erectile dysfunction in men, has been shown to
acutely enhance endothelium-dependent vasodilation in patients with heart failure (7). This
drug allows accumulation of the potent relaxing agent cGMP in vascular smooth muscle
cells by preventing its breakdown by PDE-5. Sildenafil has been shown to enhance nitric
oxide (NO)-driven cGMP accumulation in the corpus cavernosum of rabbits without
affecting cAMP formation (33). It causes mild to moderate decrease in systolic and
diastolic pressure because of the inhibition of PDE-5 in smooth muscle cells in the
vascular bed (13). Interestingly, our laboratory recently observed that sildenafil induced
both acute and delayed cardioprotective effects against ischemia-reperfusion injury in
rabbits which was dependent on the opening of mitochondrial ATP-sensitive potassium
(mitoKATP) channel (23). In addition, we demonstrated that sildenafil induced delayed
preconditioning in the mouse heart through increased expression of inducible nitric oxide
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synthase (iNOS) (31). However, the signaling mechanism involved in cardioprotection is
currently unknown.
Several studies suggest that protein kinase C (PKC) activation plays an important
role in the mechanism of preconditioning (1, 2, 15, 17, 26, 37). The PKC family of
isozymes has three major subgroups: the conventional, calcium-dependent (α-, ßI-, ßII-,
and γ), the novel, and calcium-independent PKC isozymes (δ-, ε-, η-, θ-, and possibly µ).
Translocation of PKC isoform(s) from the cytosolic to the particulate fraction (including
sarcolemmal, mitochondrial as well as nuclear fractions) result in their binding to specific
receptors of activated C kinase (RACKs) localized in membranes (20, 21). Translocated
specific PKC isoforms are believed to participate in several functions including the
opening of mitoKATP channels or the induction of gene expression (9, 34, 35). It has been
shown that PKC-mediated cardioprotection is isoform specific: the ε and η-isoforms play
an essential role in the development of ischemic preconditioning in rabbit myocardium (4,
15, 16, 27, 29). In addition, a number of pharmacological agents cause cardioprotective
effect through selective translocation of PKC isoforms to the membrane fractions (14, 32,
40). However, the role of PKC or translocation of specific isoform(s) following sildenafil
induced cardioprotection is not known. Accordingly, the goal of the present investigation
was (a) to show if the cardioprotective effects of sildenafil is blocked by the PKC inhibitor,
chelerythrine in the rabbit heart and (b) to determine whether sildenafil induces
translocation of specific isoform(s) of PKC from the cytosolic to the particulate fraction.
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MATERIALS AND METHODS

Experimental Protocol. All animals were subjected to an infarction protocol
consisting of 30 min of sustained ischemia by occlusion of the coronary artery followed by
180 min of reperfusion (Figure 1A). The effect of sildenafil was studied in the absence or
presence of chelerythrine chloride. The myocardial infarction protocol was carried out 60
min after treatment with sildenafil. The rabbits were randomly assigned into one of the
following groups. Group I: (saline control, n=6): Rabbits received 0.9 % saline; Group II:
(Sildenafil, n=6): The Viagra tablets were crushed, dissolved in water and given orally to
the rabbits. Because there is 40% bioavailability of sildenfil citrate after oral
administration, we used double the dose of the intravenous route; i.e. 1.4 mg/ kg, which is
equivalent to clinical dose of 100 mg for a 70-kg patient. Our previous study (23) has
shown that an oral dose of 1.4 mg/kg is as potent as the intravenous dose of 0.7 mg/kg in
cardioprotection. In addition, a group of animals were given sildenfil cytrate (0.7 mg/kg)
as an IV bolus, the clinical dose of 50 mg administered to a 70 kg patient (28). Group III:
(Sildenafil + Chelerythrine):

Chelerythrine chloride was dissolved in DMSO (25

mg/2.5ml DMSO) and 5 mg/kg chelerythrine was administered 5 min prior to sildenafil
treatment. Group IV: (Cheleryhtrine): Chelerythrine was given alone without sildenafil.
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Group V (DMSO): DMSO, the solvent for chelerythrine, was administered 35 min prior to
ischemia/reperfusion protocol.
Surgical Preparation. The surgical protocol is identical to that discussed in
Chapter 2.

Measurement of Hemodynamics. The method of measuring hemodynamics used in
Chapter 2 was applied in this study.

Measurement of subcellular distribution of PKC isozymes.

For measurement of

PKC, rabbits were administered sildenafil (1.4 mg/kg) or saline orally and hearts were
excised 30, 60 and 120 minutes later (Figure 1B). The left ventricle was dissected and
stored in liquid nitrogen until used. The frozen tissue samples were ground in a pre-chilled
mortar and pestle under liquid nitrogen. Total cellular proteins were obtained by glassglass homogenization of the powdered tissue in 3 ml extraction buffer containing 50 mM
Tris-HCl (pH 7.5), 5 mM EDTA, 10 mM EGTA, 50µg/ml PMSF, protease inhibitor
cocktail (10µl/ml, Sigma, product No. P8340), 0.3% β-mercaptoethanol as described by
Qiu et al. (29). The homogenates were centrifuged at 45,000g for 30 min at 4oC. The
supernatant containing cytosolic protein was saved, and the pellet was re-suspended in 3
ml of same extraction buffer along with 1% (v/v) Triton X-100 and incubated on ice for 1
hr and centrifuged at 45,000g for 30 min to obtain supernatant (particulate fraction). The
protein concentration was determined using Bio-Rad Protein Assay kit (BioRad, Hercules,
CA).
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Cytosolic and membrane fractions (100 µg protein) were separated by SDS-PAGE
on 10% denaturing acrylamide gels and transferred to nitrocellulose membranes. The blots
were blocked with 5 % nonfat dry milk in TBST buffer (10 mM Tris-HCl, pH 7.4, 100
mM NaCl and 0.1% Tween 20) for 1h. The blots were then incubated with 1,000 fold
diluted primary antibodies against respective PKCs (Santa Cruz Biotechnology, California;
cPKCα (SC-8393); cPKCβ1, (SC-8049); nPKCδ (SC 8402); nPKCε (SC-1681); nPKCθ
(SC-1680) to assess the expression of individual PKC isoform. To normalize for loading of
protein, we used ß-actin antibody (Sigma, A-2172). After 2 hrs of incubation with
respective primary antibodies, the blots were washed and incubated with anti-mouse
horseradish peroxidase-conjugated secondary antibody (1:2000 dilution, Amersham
Pharmacia Biotech, UK) for 1hr. The blots were developed with the use of a
chemiluminescent system (ECL kit, Amersham). Each immunoblotting experiment was
repeated twice and the results were averaged. For quantifying the protein translocation, the
optical density for each blot was scanned and analyzed with a densitometric system
(Bioquant 98).

RESULTS

Infarct size. Figure 2A shows infarct size expressed as the percentage of risk area.
Preconditioning with sildenafil resulted in a significant decrease in the infarct size from
33.65±2.17 in the control (saline) group to 15.07±0.63 in the sildenafil treated rabbits, a
45% reduction compared to the vehicle (mean ± SEM, p<0.05). The infarct size increased
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significantly to 31.14±2.4, (p<0.05) with chelerythrine when given 5 minutes prior to
sildenafil treatment. Chelerythrine alone had an infarct size of 33.5±2.5, which was not
significantly different when compared to the DMSO (solvent of Chelerythrine) treated
group (36.9±2.3). A similar trend in the changes in infarct size was observed when
expressed as a percentage of the left ventricle (not shown). Similarly, the differences
between the risk areas expressed as a percentage of the left ventricle were not statistically
significant between the groups (Figure 2B). These data suggest that changes in the infarct
size observed among various groups were not related to the percentage of the area of the
left ventricle that was occluded by our technique. The infarct size (% of risk area) was
reduced by 68% when sildenafil was administered intravenously (from 33.8 ± 1.7 in the
saline-treated control group to 10.8 ± 0.9 in the sildenafil treated rabbits). This infarct size
reduction was blocked by chelerythrine.

Hemodynamics. The heart rate, MAP and RPP are shown in Table 1. The heart rate,
MAP and RPP remained reasonably stable throughout the experimental period, although
they gradually decreased in most of the groups. Except at the indicated time points, the
mean values were not significantly different between the groups at any time point within
the groups.

Translocation of PKC Isoforms. We examined the sub-cellular distribution of five
PKC isoforms (α, β1, δ, ε and θ) after 30, 60 and 120 min of oral administration of
sildenafil by Western blot with the use of isoform-specific antibodies. As shown in Figure
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3, PKC isoforms α, β1, δ, θ and ε isoforms were expressed in both cytosolic and membrane
fractions. The subcellular distribution of these isoforms was generally higher in the cytosol
as compared to the membrane fraction. No significant change of the translocation of
PKCα occurred from cytosol to membrane after 30 minutes of sildenafil treatment
compared to control (saline treament) (Fig.3A). However, an increase in membrane PKCα
was observed at 60 minutes, which reached significantly higher levels by 120 minutes of
sildenafil administration. PKCθ and δ exhibited significant increase of the translocation in
the membrane fraction after 30 min to 120 min of sildenafil admistration compared to
control (Fig. 3B, C). Quantitative analysis showed increase of PKCα/β-actin ratio in the
membrane fraction by sildenafil from 0.52±0.06 (in control) to 0.70±0.04 after 120 min
(p<0.05) (Fig.3A). The ratio of PKCθ/β-actin in the membrane fraction increased from
0.62±0.06 in saline control to 0.87±0.08 (p<0.05) after 120 min of sildenafil treatment
(Figure 3B). Similarly, PKCδ/β-actin ratio in the membrane fraction increased from
0.74±0.06 (control) to 0.94±0.03 (sildenafil) (p<0.05) by 120 min of sildenafil treatment
(Fig. 3C). In contrast no significant increase of translocation of PKCβ (Fig. 3D) and ε (Fig
3E) to membrane occurred following sildenafil treatment.
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DISCUSSION

The use of sildenafil for treatment of erectile dysfunction by many patients with
cardiovascular disease has resulted in a tremendous interest in the cardiovascular
properties of the drug (3). Recently we reported that administration of sildenfil induced
cardioprotection as indicated by significant reduction in the infarct size when compared to
the controls (23). In addition, we showed that sildenafil induced delayed cardioprotective
effect in the mouse heart through upregulation of iNOS and eNOS (31). The hypothesis
behind these studies was that vasodilatory action of sildenafil could potentially release
endogenous mediators of preconditioning such as adenosine, bradykinin, or NO. One or
more of these mediators may trigger signaling cascade leading to opening of the mitoKATP
channel resulting in acute and delayed cardioprotective effects (23). There is substantial
experimental evidence that one of the major intracellular signal transduction pathways
controlling cardiac protection by ischemic preconditioning involves activation of PKC (24,
36). The question posed in this study was whether PKC plays a pivotal role in sildenafilinduced cardioprotection and to identify the specific isoform(s) may be involved in the
protective role of sildenafil. Our data show that translocation of PKC -θ and -δ started to
increase after 30 min of sildenafil treatment, reached to significantly increased level after
120 min of sildenafil treatment, which coincided with the ischemia protocol performed 60
min after oral administration of sildenafil. Although statistically non-significant, there was
well-defined trend towards increase in the translocations of PKC -α, -θ and -δ with respect
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to control at 30 and 60 min after sildenafil treatment. Our data shows that administration
of chelerythrine, the blocker of PKC prior to sildenafil abolished the infarct limiting effect
of sildenafil following ischemia/reperfusion. The reduction in infarct size was not altered
by vehicle (i.e., DMSO) confirming that the blockade of protection was indeed due to
chelerythrine only. Furthermore, chelerythrine did not have significant effect on infarct
size in the sham ischemic/reperfused rabbit hearts suggesting that PKC antagonist
interceded the signal transduction cascade during sildenafil treatment only. These data
strongly indicate that PKC activation plays an important role in the signaling mechanisms
leading to sildenafil-dependent cardiac protection in the rabbit heart.

Endogenous PKC exists in various isoforms with specific tissue distribution and
sensitivity. Translocation of PKC from cytosolic to particulate compartments is commonly
used as an index of PKC activation which is not only limited to sarcolemmal membrane
but also to cytoskeletal, mitochondrial and nuclear fractions. In the present study, we
identified and quantified different isoforms of PKC from cytosol and membrane fractions.
Our results show significant translocation of PKC-α after 60 minutes of treatment with
sildenafil. PKC-α is the major calcium dependent PKC isoform located in the soluble
fraction in resting neonatal cardiac myocytes and an increase in calcium concentration
selectively translocates PKC-α to the particulate fraction (30). The activation of PKC-α is
essential for the regulation of the Raf-Ras-Erk cascade by IGF1 (insulin-like growth factor
1) (25) or by hypertrophic signaling in adult rat cardiomyocytes (10). Our results also
showed significant translocation of PKC θ and δ from 30 min to 120 min by sildenafil.
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While the translocation of PKC-α, δ and ε have been studied in various models of ischemic
and pharmacological preconditioning, the role of PKC-θ in cardioprotection remains
unknown. PKC-θ is present in T lymphocytes as well as skeletal muscle, and its role in T
cell signaling has been studied extensively (11). In the primary myotubes from neonatal
mouse hind limb muscle, a rapid translocation of PKC-θ to the membrane in response to
treatment with the cholinergic receptor agonists, carbachol has been demonstrated (12). It
was suggested that recruitment of PKC-θ to the membranes of myotubes following
carbachol treatment plays a role in modulation of the function of membrane proteins,
including receptors. Carbachol and PMA also caused an increase in PKC-α levels in the
cytosol followed by its increase in membrane fractions (12). Inagaki et al. (6) showed that
JTV519, a novel drug that has protective effect against Ca2+ overload-induced myocardial
injury, provided anti-ischemic effect via specific activation of PKC-δ in rat hearts.
Miyawaki and Ashraf (18) demonstrated that high calcium preconditioning evoked the
translocation of PKC-α and PKC -δ to the cell membrane. In addition, PKC- was
translocated to the intercalated disk and suggesting that PKC- may modulate myocardial
function through cell-to-cell interactions. Kawamura et al., 1998 (8) showed that ischemic
preconditioning translocates PKC-α, -δ and -ε, but translocation of PKCα was transient in
isolated rat heart. Under low Ca2+ perfusion, preconditioning suppressed translocation of
PKC-α, and -ε, but not PKC-δ suggesting that the translocation of calcium-independent
PKC-δ is essential for mediating ischemic preconditioning. The difference of the
preconditioning procedures may also influence the importance of the PKC isoforms in
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mediating the protective effect (8). Pathophysiological stimuli including heat shock and
combination of heat shock and ischemic preconditioning also resulted in the translocation
of PKC-α and -δ in young rats (5) further supporting the importance of these isoforms for
the signaling cascade in cardioprotection. The downstream targets of PKC mediated
cardioprotection involves multiple signaling pathways which include activation of MAP
kinases e.g. ERK 1/2 and p38 kinases (19, 22, 26, 38, 41). Recently, we demonstrated an
essential role of PKC-δ in the delayed cardioprotection triggered by stimulation of
adenosine A3 receptor subtype in the mouse (40). In these studies, the selective early
translocation of PKC-δ in the membrane fraction initiated downstream signaling involving
activation of transcription factor NFκβ, generation of NO and opening of the
mitochondrial KATP channels (39), the possible mediators of delayed pharmacological
preconditioning in the heart.

In conclusion, for the first time we have demonstrated that sildenafil-induced
cardioprotection is dependent on activation of PKC. Our results also show that selective
translocation of three PKC isoforms (i.e., α, δ, θ) from cytosol to membrane fractions
suggesting their potential role in sildenafil-induced cardioprotection.

Further

investigations are needed to determine the cause and effect of each of the translocated PKC
isozymes in sildenafil-induced cardioprotection and to understand the mechanism(s) by
which translocated isozymes orchestrate downstream targets involved in attenuation of
ischemic injury. These studies would help in expanding our knowledge on using this drug
for protection of ischemic myocardium in humans.
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FIGURE LEGENDS

Figure 1. Experimental protocols showing (A) Infarct study after oral administration of
sildenafil citrate and/or intravenous administration of PKC inhibitor-chelerythrine and (B)
PKC measurement following oral administration of sildenafil.

Figure 2. Bar diagram illustrates infarct size (% risk area) (A) and risk area (% left
ventricle) (B) after oral administration of sildenafil citrate and/or intravenous
administration of PKC inhibitor- chelerythrine following ischemia and reperfusion. Saline
control, rabbits received 0.9 % saline. Sil, rabbit received 1.4 mg/kg sildenafil 60 min
before ischemia-reperfusion. Sil + Che, chelerythrine was administered 5 min. prior to
sildenafil

treatment.

Che,

chelerythrine

was

given

alone
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min

before

ischemia/reperfusion. DMSO, the solvent for chelerythrine was administered alone 65 min
prior to ischemia/reperfusion protocol. Results are means ±SE in 6 rabbits in each group.
*P< 0.05 compared with saline control, sildenafil, sildenafil + chelerythrine , chelerythrine,
and DMSO.

Figure 3. Effect of sildenafil on subcellular localization of PKC-α (A), -θ (B), -δ (C), -β
(D) and -ε (E) in rabbit heart. Western blot showed subcellular distribution of PKC
isoforms between cytosolic and membrane fractions after 30 min (S-30min), 60 min (S60min) and 120 min (S-120min) treatment with sildenafil. Densitometric analysis showed

86
the average of the ratio of each isoform with respect to β-actin level from 4 individual
hearts per treatment group. *P< 0.05 compared with saline control and S-120 min.

ABBREVIATIONS : Che, Chelerythrine; PKC, Protein kinase C; Sil,
Sildenafil Citrate(Viagra).
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Table 1. Hemodynamic Data

Baseline

Preischemia

30-min
Ischemia

Group I. (Saline Control, n=6)
209 ± 9
HR
199 ± 8
213 ± 9
MAP
79 ± 4d
94 ± 3
84 ± 4d
RPP
21072 ±
20896 ±
19067 ±
950a,b,c
842
781a
Group II. (Sildenafil, n=6)
216 ± 18
210 ± 20
HR
216 ± 5
MAP
96 ± 6
95 ± 3
100 ± 2
RPP
23137 ±
22848 ±
24859 ±
1617
2027
239
Group III. (Sildenafil + Chelerythrine, n=6)
172 ± 15
HR
181 ± 18
188 ± 9
MAP
78 ± 5d
102 ± 6
93 ± 4
RPP
14,573 ±
19,906 ±
15,002 ±
1579a,e
688
1181a,e
Group IV. (Chelerythrine, n=6)
188 ± 8
200 ± 7
HR
210 ± 8
MAP
80 ± 4
84 ± 2
88 ± 4
RPP
18,398 ±
20,259 ±
23,478 ±
1475a,d
1202
1021b,c
Group V. (DMSO, n=6)
209 ± 4
HR
177 ± 11
200 ± 5
MAP
66 ± 4a
90 ± 16
77 ± 11
RPP
17,585 ±
18,345 ±
15,175 ±
846a,b
1021
625a,e

Reperfusion

Reperf

(120 min)

(180 min)

191 ± 10
73 ± 3d
16138 ±
855a,d,e,f

182 ± 10
72 ± 3d
15341±
978d,e,f

179 ± 10
67 ± 2d,e
13969 ±
819a,d,e

205 ± 14
89 ± 0.4
21647 ±
2274

187 ± 9
82 ± 5d
17738 ±
860d

187 ± 9
81 ± 5d
18555 ±
1336

194 ± 19
69 ± 5d
14,644 ±
964a,e

182 ± 17
72 ± 5d
14,647 ±
1482e

186 ± 18
67 ± 11d
14,261 ±
1330a,e

178 ± 7
78 ± 6
14,901 ±
975a,d,e

171 ± 7d
70 ± 6
16,987 ±
1215d

168 ± 11d
71 ± 6
13,579 ±
986a,d,e,f

200 ± 16
66 ± 11
13,902 ±
423a,d,e

195 ± 4
68 ± 12
15,313 ±
213e

194 ± 2
67 ± 10
15,102 ±
547a,e

Reperfusion

(60 min)

Values are means±SEM. HR-Heart Rate (beats/min); MAP-Mean Arterial Blood
Pressure (mmHg); RPP- Rate Pressure Product (mmHg) aP<0.05 vs.Sildenafil;
b
P<0.05 vs.Sildenafil+ Chelerythrine; cP<0.05 vs DMSO; dP<0.05 vs. Baseline;
e
P<0.05 vs. Pre-ischemia; fP<0.05 vs. 30-min Ischemia.
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CHAPTER 5
Sildenafil Citrate (Viagra) Induces Cardioprotective Effects Following IschemiaReperfusion Injury in Infant Rabbits

YVONNE A BREMER, FADI SALLOUM, RAMZI OCKAILI, ERIC CHOU,
WILLIAM B. MOSKOWITZ, AND RAKESH C. KUKREJA
Division of Pediatric Cardiology, Department of Pediatrics [Y.A.B., W.B.M.],
Division of Cardiology, Department of Medicine [F.S., R.O., E.C., R.C.K.],
Virginia Commonwealth University Health System, Richmond, Virginia, U.S.A.
Published in Pediatric Research in 2004.
ABSTRACT
Infants undergoing surgery for congenital heart disease are at risk for myocardial
ischemia during cardiopulmonary bypass, circulatory arrest, or low flow states.

The

purpose of this study was to demonstrate the effects of sildenafil, a selective
phosphodiesterase-5 (PDE-5) inhibitor on myocardial functional improvement and infarct
size reduction during ischemia/reperfusion injury in infant rabbits. Infant rabbits (aged 8
weeks) were treated with sildenafil citrate (0.7 mg/kg IV) or normal saline 30 minutes
prior to sustained ischemia for 30 minutes and reperfusion for 3 hours. Transesophageal
echocardiography (TEE) was utilized to assess left ventricular cardiac output (LVCO) and
aortic Velocity Time Integral (VTI).

Following ischemia/reperfusion, risk area was

demarcated by Evan's blue dye and infarct size determined by computer morphometry of
triphenyltetrazolium chloride stained sections.

The sildenafil-treated group had
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preservation and elevation in LVCO (143% of baseline, p<0.05) and an elevated aortic
VTI (145% of baseline, p<0.05) following 30 minutes of ischemia compared to the control
group LVCO (72% of baseline, p<0.05) and aortic VTI (73% of baseline, p<0.05). This is
a statistically significant increase in LVCO and aortic VTI in the sildenafil group
compared to controls (n=6/group, p<0.05). The sildenafil treated group had significant
reduction in infarct size (15.5 ± 1.2 versus 33 ± 2.3 in the saline group, % risk area, mean ±
SEM, n=10-15/group, p<0.05). For the first time, we have shown that sildenafil citrate
promotes myocardial protection in infant rabbits as evidenced by post-ischemic
preservation and elevation in LVCO and aortic VTI and reduction in infarct size.

Abbreviations
PDE-5, phosphodiesterase-5
TEE, transesophageal echocardiography
LVCO, left ventricular cardiac output
VTI, velocity time integral
TTC, 2,3,5-triphenyltetrazolium chloride
LAD, left anterior descending
LV, left ventricle
LVOT, left ventricular outflow tract
HR, heart rate
MAP, mean arterial pressure
SVR, systemic vascular resistance
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Each year, more than 25,000 children undergo corrective surgery for congenital
heart disease. Early surgical intervention is important to promote more normal
development. Infants undergoing surgery for congenital heart disease are at risk for
myocardial ischemia during cardiopulmonary bypass, circulatory arrest or low flow states
(1). Less is known about the tolerance of the infant myocardium to ischemia compared to
the adult, and cardiac reserves are more limited in the infant (2). Although there is
evidence that the infant myocardium may be more resilient to metabolic or ischemic injury
compared to adults, the infant heart responds quite differently to cardiovasular drugs,
stress, and changes in hemodynamics (3,4).

Although hypothermia combined with

pharmacologic cardioplegia protects the globally ischemic adult heart, this benefit may not
extend to infants. For example, poor post-ischemic recovery of function and increased
mortality may result when this method of myocardial protection is used in children (5).
Therefore, there is a need to develop novel pharmacological approaches to protect the
infant hearts from ischemia/reperfusion injury.
Brief episodes of ischemia protect the myocardium from more prolonged periods of
ischemia, a phenomenon called ischemic preconditioning (6). A variety of other stimuli,
such as hypoxia, thermal stress, pharmacologic agents, and endogenous triggers of
preconditioning such as nitric oxide and adenosine have also been shown to induce
cardioprotective effects in several animal species (7-10). Also, recent studies from our
laboratory have shown that sildenafil citrate (Viagra), a selective phosphodiesterase-5
(PDE-5) inhibitor, induces powerful preconditioning-like protective effects in the ischemic
heart (11). However, it is not known whether sildenafil exerts similar protective effects
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against ischemia/reperfusion injury in the infant rabbit hearts as well. The purpose of this
study was (a) to show if pretreatment of infant rabbits with clinically relevant dose of
sildenafil improves post-ischemic myocardial function and (b) to demonstrate if this drug
reduces myocardial infarct size following ischemia/reperfusion. We used the model of
coronary artery occlusion and reperfusion in infant rabbits, which is similar to our
previously described adult rabbit model of myocardial infarction (11). This model may be
applicable in pediatrics, and especially in pediatric cardiovascular surgery where there may
be periods of ischemia/reperfusion injury. Also, for the first time, we used 2-dimensional
(2D) and Doppler transesophageal echocardiography (TEE) for the estimation of left
ventricular cardiac output (LVCO) and aortic velocity time integral (VTI) in this model.
METHODS

Animals. Eight-week-old male New Zealand White rabbits with mean weight of 2.0 kg
(range 1.3 kg-2.6 kg) were used for the study. We chose Eight-week-old rabbits because
they are similar in size to human neonates or young infants who undergo surgery for
congenital heart disease early on in life. We believe this model to be different from the
adult rabbit model as well as helpful and similar to young human infants because of similar
size, presence of thymic tissue (and thus not having had undergone significant stress yet),
and being prepubertal. We thus believe that the physiology and responses to stress and
ischemia may be similar to that of human infants.
Study Protocol. Anesthesia and Infarction protocol are similar to those in Chapter 2.
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TEE. Transesophageal echocardiography, using a 10 Fr AcuNav diagnostic ultrasound
probe, was performed at baseline, following the 30 minute period of ischemia, and after 3
hours of reperfusion in both the control and sildenafil groups. Standardized 2D imaging in
a long axis view of the left ventricle (LV) to show LV inflow across the mitral valve and
left ventricular outflow tract (LVOT) was obtained (12) (Fig. 1). Aortic flow Doppler
across the aortic valve was performed in a long axis view of the LV and LVOT to obtain
LVCO (Fig. 2). The standard equation: Mean Velocity (cm/s) x flow area (cm2) x 60
(s/min), where Mean Velocity (cm/s) = VTI (in cm/beat) ÷ RR interval in s/beat, was used
to obtain LVCO expressed in mL/min (12,13). Laminar Doppler flow across the aortic
valve confirmed the absence of aortic stenosis. Color Doppler assessment was made of
both the aortic and mitral valves again in the long axis view at baseline, after the ischemic
period, and following 3 hours of reperfusion for the presence or absence of mitral or aortic
regurgitation. Subjective functional assessment was also made following ischemia and
reperfusion to demonstrate at least left ventricular apical diminished contractility to
confirm infarction.
Measurement of Infarct Size.
dicussed in Chapter 2.

The same methodology was used here as previously
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RESULTS

Animals and Exclusion. A total of 34 rabbits were used in the study; 20 in the sildenafil
group and 14 in the control group. 2 rabbits in the control group died before completion of
the 3 hour reperfusion period due to hypotension, arrhythmias and acidosis. TEE was
performed on 12 rabbits; 6 in the sildenafil group and 6 in the control group. 2 rabbits in
the control group did not undergo TEE following 3 hours of reperfusion due to technical
difficulties with the TEE machine. A total of 25 rabbit hearts were examined for infarct
size, 15 in the sildenafil group and 10 in the control group. The 9 rabbit hearts that did not
stain well were excluded from the study.
Hemodynamics. Changes in hemodynamics are summarized in Table 1. The rabbits
treated with sildenafil had a 34% decline in mean arterial pressure (MAP) and 8% increase
in heart rate (HR) following drug administration as compared to the controls (p<0.05).
However, MAP and HR were comparable in both groups prior to the ischemic period.
Following 30 minute ischemia, MAP and HR were also comparable in both the groups
although a significant decline in MAP as compared to the baseline values was observed.
This drop in MAP persisted through 3 hours of reperfusion, which represented a 19% and
18% decrease for the sildenafil and the control group respectively, compared to baseline
values (p<0.05).
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TEE. Both the control and sildenafil-treated groups had comparable LVCO and aortic
VTI at baseline.

The controls had a decline in LVCO and aortic VTI immediately

following the 30 minute period of ischemia (28% and 27% lower than baseline values,
respectively, p<0.05), whereas the LVCO and aortic VTI increased in the sildenafil group
following ischemia (43% and 45% higher than baseline values, respectively, n = 6 per
group, p<0.05). Both groups, however, had significant decline in LVCO following 3 hours
of reperfusion (54% of baseline in the sildenafil group, p<0.05, and 62% of baseline in the
control group, p<0.05), and were not statistically significantly different from each other (n
= 4-6 per group). Both groups demonstrated a decrease in aortic VTI following 3 hours of
reperfusion. However, this decline was only statistically significant in the control group
compared to baseline values. Changes in LVCO and aortic VTI are shown in Figure 3.
None of the rabbits had aortic stenosis or developed aortic regurgitation for the duration of
the study. Both the control and sildenafil groups demonstrated a comparable amount of
mitral regurgitation (no more than mild) following ischemia/reperfusion, and none of the
rabbits had baseline mitral regurgitation.
Infarct Size. Figure 4 shows risk area (% LV) and infarct size expressed as the % of risk
area. Pretreatment with sildenafil resulted in a decrease in the infarct size from 33 ± 2.3 in
the control group to 15.5 ± 1.2 in the sildenafil treated rabbits, a 45% reduction compared
to controls (p<0.05). A similar trend in the changes in infarct size was observed when
expressed as % of LV (not shown). Similarly, the differences between the risk areas were
not statistically significant between the two groups. These data suggest that changes in the
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infarct size observed in the two groups was not related to the % of the area of LV occluded
by our technique.

DISCUSSION

The use of sildenafil for treatment of erectile dysfunction by many patients with
cardiovascular disease has resulted in a tremendous interest in the cardiovascular
properties of the drug (14). Recent studies in rats have shown that PDE-5 inhibition with
sildenafil attenuated the rise in pulmonary artery pressure and vascular remodeling when
given before chronic exposure to hypoxia and when administered as a treatment during
ongoing hypoxia-induced pulmonary hypertension (15). Clinical investigations in patients
with pulmonary arterial hypertension have also shown that sildenafil therapy may be of
benefit in patients receiving long-term infusion of epoprostenol (16,17). Recently we
reported that administration of sildenfil induced cardioprotection as indicated by
significant reduction in infarct size when compared to controls (11,18). In addition, we
showed that sildenafil induced delayed cardioprotective effect in the mouse heart through
upregulation of iNOS and eNOS (19). The hypothesis behind these studies was that the
vasodilatory action of sildenafil could potentially release endogenous mediators of
preconditioning such as adenosine, bradykinin, or NO. One or more of these mediators
may trigger a signaling cascade leading to activation of protein kinase C (20) and opening
of the mitoKATP channel resulting in acute and delayed cardioprotective effects (11). In the
present study, we have shown that sildenafil citrate also induced cardioprotection against
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ischemia/reperfusion injury in infant rabbits. This is evident from preservation of postischemic cardiac output and significant reduction in infarct size.
Hemodynamics.

Sildenafil citrate had a direct effect on hemodynamics by causing

transient hypotension, which may have resulted in increased heart rate either directly or
indirectly. Both groups developed the same degree of hypotension following ischemia
even though the sildenafil-treated group had increased LVCO and aortic VTI. This may
reflect sildenafil’s effect on the lowering of systemic vascular resistance (SVR). Since
hypotension was again observed following the 3 hour reperfusion period in both groups,
and LVCO was comparable even though infarct size was reduced in the sildenafil group, it
is likely that LVCO and aortic VTI may be predominantly related to SVR. We believe that
sildenafil’s effect on SVR, which is not directly measured by pressure and heart rate,
caused such a profound change and increase in cardiac output. Thus, it is also possible that
the additional benefits of sildenafil may be short-lived. Our results suggest that multiple
mechanisms may be involved in myocardial preservation with sildenafil infusion. This
may include a preconditioning-like effect as well as a direct effect on hemodynamics. The
drop in MAP in both groups following the 3 hour reperfusion period may reflect the fact
that all rabbits were under general anesthesia for the duration of the experiment. The
rabbits did receive 50cc/hr of normal saline (~25cc/kg/hr), which is the approximate
equivalent of several fluid boluses as given to human infants, although infused more
slowly. Since urine output was maintained throughout the experiment, we believe that
renal function was preserved, and any excessive volume infused would have been
accounted for by adequate urine output.

We would have expected hypertension and
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bradycardia, or similar echocardiographic findings of increased output due to increased
preload in both groups if volume had been an issue. Thus it is unlikely that volume
infusion alone led to hemodynamic deterioration in both groups after the reperfusion
period.
Functional assessment. In the present study, we used 2D and Doppler echocardiography
for the estimation of LVCO and aortic VTI. This may be a better marker for preserved or
increased cardiac output. The use of TEE in the infant rabbit provided a long axis view of
the LV and LVOT to make these calculations. This view also showed the mitral valve and
a selective plane of the left ventricular myocardium. LVCO was preserved in the sildenafil
treated group mainly because of increased aortic VTI. Aortic VTI, when multiplied by
cross-sectional area, gives a volume measurement, or in this case left ventricular stroke
volume (13,21). When this is multiplied by heart rate, it gives left ventricular cardiac
output (13,21). Heart rate was similar in both groups following ischemia and reperfusion,
so can not be assumed to be the major determinant. In addition, the cross-sectional area of
the aortic valve annulus remained essentially unchanged as well. LVCO was elevated in
the sildenafil group compared to its baseline values and compared to the control group
following the ischemic period. Since cardiac output is a function of preload, afterload, and
contractility, this demonstrates the beneficial effects of sildenafil in preserving myocardial
function through its effect on hemodynamics and SVR (afterload). We believe that
sildenafil’s effect on SVR, which is not directly measured by pressure and heart rate,
caused such a profound change and increase in cardiac output. We can not assume this is
due to myocardial contractility alone (since this was not directly measured).

It is likely
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that sildenfil’s role in opening of mitoKATP channels contributed to less myocardial
necrosis, and subsequently enhanced contractility, although this does not explain the
decline in function in both groups following the 3 hour reperfusion period. Perhaps to a
lesser extent, sildenafil inhibited the degradation of cAMP (by its minor role in inhibiting
PDE-3), and subsequently led to accumulation of ATP and improvement in contractility.
In addition, it is possible that sildenafil may cause coronary vasodilation and thus lead to
enhanced local and selective myocardial perfusion following an ischemic period, and
again, improvement in contractility. The decline in cardiac output following 3 hours of
reperfusion in both groups suggests that functional protection with sildenafil may be shortlived, and again, predominantly related to SVR. It may also be related to undefined
actions of the drug itself that have yet to be determined.

Infarct Size. In the present study, we observed significant decrease in the infarct size in
the sildenafil treated group as compared to control rabbits. However the degree of infarct
reduction was 53 % in the infant model as compared to 68 % in the adult rabbits (11)
during acute pretreatment with sildenafil. The drug provided 75 % reduction in infarct size
24 hrs after treatment in the mouse model of global ischemia and reperfusion (19). The
reason for these variations is not clear although it may be related to the physiologic
differences in the resistance of the infant myocardium to ischemia or stress versus the
difference in response of the infant myocardium to cardiovascular drugs. Although the
infant myocardium may be more tolerant of ischemia only, its response to stress,
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hemodynamic changes, and pharmacologic agents may be very different, thus rendering
the myocardium more susceptible to injury.

Study limitations. When using Doppler echocardiography to calculate LVCO, there are
several fundamental assumptions. First, that flow is laminar and organized; second, that
the velocity profile is uniform across the aortic valve outlet; third, that the point of outflow
used to calculate vessel cross-sectional area is circular; and fourth, that the point of
measurement of cross-sectional area remains relatively constant without significant
changes with hemodynamics (13,21). We made every attempt to record Doppler tracings
with the Doppler beam parallel with flow in the vessel and just above the aortic valve
annulus, as this is the point at which maximal flow velocity should theoretically occur
(13). We also measured the cross-sectional area at the aortic valve annulus, as this area
should be the flow-limiting point and most constant in relation to changes in
hemodynamics (13).

Since LVCO is preload dependent, the presence of mitral

regurgitation or aortic regurgitation may potentially have an effect on cardiac output.
Although we did not account for the volume of mitral regurgitation, we did assess for its
presence or absence. Since this amount was subjectively similar in both groups, we
assumed that LVCO would not be substantially affected in either group. Neither group
developed aortic regurgitation. Our study is also limited to a single 2D image of the long
axis of the left ventricle. This view is not able to assess all segments of the left ventricular
myocardium to quantitate regional wall motion abnormalities. Although we were able to
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subjectively determine diminished apical myocardial contractility following infarct, we
limited our study to the assessment of aortic VTI and LVCO.

Clinical implications. For the first time, we have shown that sildenafil treatment resulted
in post-ischemic early improvement in cardiac output during ischemia/reperfusion in infant
rabbits.

In addition, the drug caused significant reduction in infarct size following

ischemia/reperfusion. Further studies are needed to determine the effects of hypotension
alone, as well as duration and timing of drug administration on sustained preservation of
myocardial function during reperfusion or days later during recovery. Since less is known
about the optimum method of myocardial preservation in infants compared to adults, there
is impetus for studying and developing different strategies for improved surgical outcome.
In addition, since postoperative management of infants with congenital heart disease is
complicated by various physiologic differences and responses to ischemia, stress, and
changes in hemodynamics, it is important to devise new techniques for ideal ICU care. It
is possible that sildenafil citrate may be clinically important in protection of the heart in the
setting of cardiac surgery employing cardiopulmonary bypass, circulatory arrest, or low
flow states in infants with congenital heart disease.
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FIGURE LEGENDS

Figure 1.

Still frame 2D transesophageal echocardiogram of LVOT. LA=left atrium,
MV=mitral valve, LV=left ventricle, AV=aortic valve, AO=aorta, RV=right
ventricle.

Figure 2.

Still frame Doppler across aortic valve, velocity vs time.

Figure 3.

LVCO

and

aortic

VTI

following

sildenafil

infusion

during

ischemia/reperfusion. n = 4-6 per group. *p<0.05, †p<0.05 compared to
baseline values.

Figure 4.

Bar diagram illustrating infarct size (% risk area) in controls vs the
sildenafil group compared to risk area (% left ventricle). n = 10-15 per
group. *p<0.05.
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Table 1. Hemodynamic Data During Ischemia/Reperfusion
After
End
Baseline Saline/Drug Preischemia Ischemia
84.3±
3.4
213.8±
7.1

80.5±
3.8
212.1±
6.9

Reperfusion Time
(Hour)
1
2
3
73.1± 75.1± 75.3± 69.7±
4.3§
3.4
3.4
3.5§
206.1± 188.5± 175.3± 169.7±
6.9
7.2
8
7.4

55.9±
2.5*
236.1±
4.6*

74±
3.7†
211.8±
3.8†

70.2± 71.5± 69.2± 69.1±
4‡
3.2
2.8
2.8‡
202.2± 180.2± 174.1± 167.8±
5
6.9
7.2
7.1

Cntrl
85.4±
MAP
3.7
213.1±
HR
6.6
SIL
MAP
HR

84.8±
3.7
218.3±
6.6

Values expressed as means ± SEM. MAP=mean arterial pressure in mmHg; HR=
heart ratein beats per minute. n = 12-20 per group. *p<0.05 vs controls; †p>0.05
vs controls; ‡p>0.05 vs controls but <0.05 vs baseline; §p<0.05 vs baseline.
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CHAPTER 6

Sildenafil Induces Delayed Preconditioning against Myocardial Infarction via iNOS
Upregulation by Phosphorylation of ERK in Mouse Heart

Background: We previously demonstrated that sildenafil induces delayed preconditioning
following global ischemia/reperfusion in the mouse heart via iNOS dependent pathway
(Chapter 3). In the current study, we investigated the role of MAP kinases in sildenafilinduced cardioprotective signaling.
Methods and Results: Adult male ICR mice were pretreated (i.p.) with either sildenafil
(0.71 mg/kg, equivalent to 50 mg dose for 70 kg patient) or volume-matched saline.
Selective inhibitors of p38 MAPK (SB203580, 1 mg/kg, i.p.) or MEK1 and 2 (PD 98059, 1
mg/kg, i.p.) were administered 30 min before sildenafil. The hearts were isolated 24 hours
later and subjected to 20 min global ischemia and 30 min of reperfusion in Langendorff
mode. Infarct size was measured by computer morphometry of TTC stained sections. Postischemic myocardial infarct size (Mean±SEM; % of risk area) was reduced in mice treated
with sildenafil (6.0±1.2) versus saline group (27.6±3.3; P<0.05; n=6/each). SB203580 did
not block this protective effect (8.2±1.6 vs. 6.0±1.2 with sildenafil alone, p>0.05). In
contrast, PD98059 treatment abolished the infarct limiting effect of sildenafil (22.18±2.76,
p<0.05). Sildenafil caused increased phosphorylation of ERK1/2 but not p38 MAPK
within 30 min after treatment. Furthermore, western blot analysis showed an elevation in
iNOS protein levels 24 hrs after treatment with sildenafil, which was abolished by
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PD98059. No significant changes in ventricular contractile function and heart rate were
observed in sildenafil-treated group.
Conclusion: We conclude that the sildenafil-induced delayed protection against global
ischemia/reperfusion is mediated by signaling pathway involving phosphorylation of ERK
and the subsequent upregulation of iNOS.

INTRODUCTION

Sildenafil citrate (Viagra) is the first oral agent approved for treatment of erectile
dysfunction in men. It is a selective inhibitor of phosphodiesterase-5 (PDE-5), an enzyme
that catalyzes the breakdown of a potent smooth muscle relaxing agent cyclic guanosine
monophosphate (cGMP). Sildenafil has been shown to cause moderate decrease in systolic
and diastolic pressure because of the inhibition of PDE-5 in smooth muscles in the
vascular bed. We hypothesized that such mild vasodilatory effect of sildenafil in coronary
vasculature could potentially release vasoactive agents such as adenosine or bradykinin,
and demonstrated the role of sildenafil in increasing levels of iNOS protein which in turn
upregulate NO that may trigger preconditioning-like protective effect in the heart.
Moreover, we recently showed that sildenafil caused acute and delayed protection against
ischemia/reperfusion injury in vivo in the heart which was dependent on the opening of
mitoKATP channel [88]. These studies were performed in an in situ rabbit model where the
hearts were subjected to coronary artery occlusion followed by reperfusion. We also
illustrated that sildenafil induced a powerful delayed cardioprotevtive effect against global
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ischemia/reperfusion injury via iNOS-dependent pathway in an isolated perfused mouse
heart model [90]. However, the signaling pathway(s) that lead to such cardioprotective
effect are currently under investigation.

Recent studies suggest an important role of the MAP kinase family particularly p38 in the
early phase of ischemic preconditioning (IPC) [20], although the results have been
controversial [92]. Direct activation of p38 by anisomycin mimicked IPC and delayed
cardioprotection in the isolated perfused hearts [93,46]. The activation of p38 has also been
suggested to be the trigger of delayed preconditioning induced by adenosine. In the MAP
kinase family, the p44/p42-MAPK (Erk1/2, where Erk is extracellular-signal-regulated
kinase) cascade appears to mediate cell growth and survival signals in many cell types.
ERK activation has been shown to protect cardiomyocytes from oxidant stress [94].
Sustained activation of p44/p42-MAPK during simulated ‘reperfusion’ following sublethal
simulated ‘ischemia’ mediates preconditioning in cardiomyocytes independently of
transient activation of p38-MAPK. However there are no studies available implicating the
role of MAP kinases in sildenafil-induced cardioprotection.

The goal of the present

investigation was to 1) to show if p38 MAPK and ERK 1 and 2 phosphorylation plays role
in the sildenafil-induced cardioprotection, and 2) to investigate the role of MAPK
phosphorylation in the sildenafil-mediated increase in iNOS and eNOS protein levels.
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MATERIALS AND METHODS

Langendorff Isolated Perfused Heart Preparation
The same experimantal protocol was used as in Chapter3.

Study Protocol
Mice were randomly assigned into one of the following groups:

Group I: (saline control, n=6): Mice received 0.9 % saline, i.p.;
Group II: (Sildenafil, n=6): Viagra tablets were crushed and dissolved in saline. This
preparation was given as 0.71 mg/kg i.p. bolus, approximating, on a mg/kg basis, the
clinical dose of 50 mg administered to a 70 kg patient;
Group III: SB203580 + Sildenafil (n=6): SB203580 (1.0 mg/kg) was injected 30 min prior
to sildenafil treatment as in Group II;
Group IV: SB203580 + Saline (n=6): treatment with SB203580 alone;
Group V: PD 98059 (1.0 mg/kg) was injected 30 min prior to sildenafil;
Group VI: PD 98059 + Saline (n=6): pretreatment with PD 98059 alone;

Twenty-four hours later, the hearts were isolated and following a 30 min stabilization
period, the hearts were subjected to 20 min no-flow normothermic global ischemia and 30
min reperfusion.
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Phosphorylation of p38, ERK 1 and 2: Four animals were pretreated with 0.15 ml saline
or 0.71mg/kg sildenafil (i.p., n=2 per group). Te hearts were removed, ventricular samples
collected 30 min after treatment and immediately frozen in liquid nitrogen. The samples
were ground into fine powder in liquid nitrogen after cell lysis in 1 ml of RIPA buffer
(Upstate) containing: 5omM Tris-HCL, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid,
1% NP-40, 1mM EDTA and protease inhibitors (1nM phenylmethylsulfonyl fluoride, 1
µg/ml leupeptin, 1 µg/ml pepstatin and µg/ml aprotinin) and a phosphatase inhibitor (1
mM sodium orthovanadate). The mixture was homogenized and centrifuged at 6,000 g for
10 min. The supernatant was then collected and protein concentration was measured.
For immunoprecipitation, 300 µg of the sample protein were incubated with 5 µg of antip38 (C-20, Santa Cruz) or anti-ERK rabbit polyclonal antibody (C-14, Santa Cruz) in
500 µl of RIPA buffer for 3 h at 4°C. 35 µl of protein A/G agarose beads (Santa Cruz)
were then added to the sample and mixed for another 60 min. The agarose beads containing
the immunocomplexes were pelleted by centrifugation for 5 min (1000 g) at 4°C, and the
supernatant was carefully aspirated and discarded. The beads were washed 3 times with
RIPA buffer and 1 time with PBS by repeating the centrifugation step described above.
The beads were then resuspended in 50 µl of electrophoresis sample buffer. To dissociate
the immunocomplexes from the beads, the sample was boiled for 5 min and centrifuged
again, and the supernatant was collected. Subsequently 20 µl of immunoprecipitated
supernatant were separated by SDS-PAGE (10% polyacrylamide) and transferred to a
polyvinylidene difluoride membrane (Bio-Rad) via tank transfer for 2 h at 190 mA. After
the membrane was blocked with milk solution [5% nonfat dry milk in Tris-buffered saline

120
(TBS) with 0.05% Tween-20 (TBST)] for 1 h, it was probed with a mouse monoclonal
antibody for either phosphorylated p38 MAPK (p-p38, D-8; Santa Cruz) or phosphorylated
ERK (p-ERK, E-4, Santa Cruz); or total p38 (A-12, Santa Cruz) or ERK-2 (D-2, Santa
Cruz) [both diluted 1:500 in milk with TBST] for 2 h. After the membrane was washed
with TBST, it was incubated with an anti-mouse horseradish peroxidase-linked antibody
(diluted 1:2,000 in milk solution with TBST; Amersham) for 1 h. The membrane was
washed with TBST four times (for a total of 30 min) and then incubated using a
chemiluminescence kit (Amersham) before being exposed to X-ray film. The bands were
quantified via densitometric scanning.

Western Blot Analysis:

In brief, triplicate heart samples were collected 24 hours after

saline , sildenafil, PD98059 followed by sildenafil 30 min later, or PD98059 injection and
homogenized in ice-cold RIPA buffer (Upstate Biotechnology). The homogenate was
centrifuged at 10,000 g for 10 min under 4°C, and supernatant was recovered as the total
cellular protein. 60 µg total protein from each sample was separated by SDS/PAGE on
10% acrylamide gels and transferred to a PVDF membrane, and then blocked with 5%
non-fat dry milk in TBS.

The membrane was subsequently incubated with a rabbit

polyclonal antibody (Santa Cruz; dilution 1:500) reacting specifically to iNOS, eNOS, or
actin (for normalizing loading of protein). The secondary antibody was a horseradish
peroxidase-conjugated anti-rabbit IgG (Amersham, 1:1,000 dilution). The membranes
were developed using enhanced chemiluminescence and exposed to x-ray film.
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For quantifying protein expression, the optical density for each Western blot band was
scanned and analyzed with a densitometric system (Bioquant 98).

RESULTS

Cardiac Hemodynamics and Contractile Function:
There was no significant difference in the basal functional parameters (i.e. developed
force, rate-force product, and resting tension) between the groups after 20 min
stabilization.During post-ischemia also; there were no significant differences in the rate
force product (Figure 1). Post-ischemic coronary flow was not significantly different
among the groups except that it was slightly improved in the sildenafil-treated mice.

Myocardial Infarction:
Post-ischemic myocardial infarct size (Mean±SEM; % of risk area) was reduced in mice
treated with sildenafil (6.0±1.2) versus saline group (27.6±3.3; P<0.05; n=6/each).
SB203580 did not block this protective effect (8.2±1.6 vs. 6.0±1.2 with sildenafil alone,
p>0.05). In contrast, PD98059 treatment abolished the infarct limiting effect of sildenafil
(22.18±2.76, p<0.05). There was no significant difference in the infarct size between the
controls and the animals treated with DMSO, PD98059 and SB203580.
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Phosphorylation of p38 and ERK:
Ventricular tissue was harvested after 30 minutes of treatment with sildenafil.
Phosphorylation of p38-MAPK and p44/p42-MAPK (Erk1/2) was determined by Western
blotting using phospho-specific antisera. As shown in Figure 2, phosphorylation of both
p42- and p44-MAPK isoforms was observed. Total p42-MAPK (Erk2) is shown in the
upper panel as a loading control. Phosphorylated p38 or total p38 was not different
between control and sildenafil treated mice.

Effect of ERK activation on iNOS/eNOS protein expression:
Heart samples were collected 24 hours after saline, sildenafil, PD98059 and followed by
sildenafil, or PD98059 injection.

Protein levels of iNOS/eNOS were determined by

Western blotting. As shown in Figure 3, iNOS protein expression is increased with
sildenafil as compared to the saline control group, and this increase is completely blocked
by PD98059 pretreatment.

DISCUSSION

The expression of the iNOS gene is an important part of the body’s response to stressors by
modulating and regulating vascular smooth muscle tone and thus affecting function of
several organ systems, including the cardiovascular system. The NO generated by iNOS
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from its substrate L-arginine has beneficial effects (eg, antimicrobial, antiatherogenic,
antiapoptotic), whereas the overproduction of induced NO has detrimental consequences
(eg, direct cellular injury and proinflammatory response). Sildenafil pretreatment was
shown to induce upregulation of iNOS, but the exact mechanism of this effect is not yet
fully understood.

Studies have suggested that the iNOS gene is regulated at multiple

levels: transcriptional, posttranscriptional, and posttranslational. However, the role of the
mitogen-activated protein kinase (MAPK) cascades in the control of iNOS expression has
not been completely defined. In this study, we investigated whether the MAPK signaling
pathway was involved in the regulation of iNOS expression and whether sildenafil
influenced MAPK activity. In the present study, a single bolus injection of sildenafil of
0.71 mg/kg caused significant reduction in the infarct size 24 hrs later, when compared to
the saline-treated controls.

The selective inhibition of ERK by PD98059 completely

abolished the protective effect of sildenafil whereas p38 MAPK inhibitor SB203580 failed
to block the protection. These results are further supported by increased phosphorylation
of p44/42 sildenafil treated hearts while absence of phosphorylated p38 in the same
samples. No significant changes in the pre- or post-ischemic ventricular function were
observed between the control and treated groups. Taken together, our results show that
phosphorylation of ERK 1 and 2 mediates sildenafil induced delayed cardioprotection
against global ischemia/reperfusion injury.

The role of p38 signaling in early preconditioning has been extensively investigated,
although conflicting results have been obtained. However, relatively little is known about
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the role of MAP kinases, in particular their cause and effect during delayed
preconditioning. Ping et al [32] demonstrated that ischemic PC was associated with
activation of p44 and p42 MAPKs in rabbit hearts although the role of these kinases in
delayed protection in this model was not studied. Recently we showed that heat stressinduced delayed protection was mediated by MAP kinases. Dana et al [78] showed
transient activation of adenosine A1 receptor with 2-chloro-N6-cyclopentyladenosine
(CCPA) induced delayed preconditioning which was also accompanied by rise in the p38
activity. The delayed protection was abolished by p38 inhibitor, SB203580 in the mouse
heart suggesting an essential role of p38 in protection. Recently, we showed that selective
activation of p38 with anisomycin triggered delayed cardioprotection in the mouse heart.
In this respect, it appears that sildenafil is the first drug which mediated delayed
cardioprotection through phosphorylation of ERK 1/2.

In summary, we demonstrated that a significant ERK phosphorylation can be detected with
0.71 mg/kg i.p. administration of sildenafil, which is in a dose range that is clinically
relevant. The results provide a possible mechanism to explain the potential infarct-limiting
effect of sildenafil and suggest that ERK activation by this PDE-5 inhibitor may be
involved in the subsequent induction of iNOS expression.
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Figure Legends
Figure 1. Experimental protocol for Langfendorff isolated moude heart experiments.

Figure 2. Effect of sildenafil, SB203580, and PD98059 on ventricular functional recovery
following global ischemia-reperfusion.
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Figure 3. Effect of sildenafil on myocardial infarct size: role of p38 MAPK and p44/42
MAPK. Isolated perfused hearts were subjected to 20 min global ischemia and 30 min
reperfusion in Langendorff mode. Values are means ± SE (n = 6 heart samples per group).
Group III and V received SB-203580 (1 mg/kg, ip) or PD 98059 (1 mg/kg, ip) 30 min
before sildenafil treatment.
PD98059,

Group IV and VI served as controls for SB203580 and

respectively.

*P < 0.05 vs.

saline

control,

SB203580+saline,

PD98059+sildenafil and PD98059+saline.

Figure 4. Western blots showing MAPK phosphorylation after treatment with sildenafil.
Tissue
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Immunoprecipitates were subsequently analyzed by Western blots using a mouse
monoclonal antibody for a 1:100 dilution of either total and phosphorylated p38 MAPK or
total and phosphorylated anti-ERK 1 and 2 rabbit polyclonal antibody.

Figure 5. Western blots showing cardiac expression of iNOS and eNOS proteins 24 hrs
after sildenafil treatment with or without PD98059. Actin levels for each sample shows
equal protein loading.
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Figure 2
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Figure 3
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Figure 4

MAPKs activation by Sildenafil
p38
IMP: p38

WB: p38

ERK (p44/p42)
IMP: ERK

WB: ERK2

Total

C1 C2 S1 S2
IMP: p38

WB: p-p38

C1 C2 S1 S2
IMP: ERK

WB: p-ERK
p44
p42

Phospho-

C1 C2

S1 S2

C1 C2 S1 S2

C1 and C2 represent saline control
S1 and S2 represent sildenafil treatment

d+

PD

PD

S il

PD
PD

d+

d

S il
S il

d

S il

nt

nt

Co

Co

132

Figure 5
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CHAPTER 7

Delayed Cardioprotection with Sildenafil in Mice: Role of Adenosine A1 Receptor
and Its Genetic Deletion

Background: Since adenosine has been implicated to be a major trigger of schemic and
pharmacological PC, we tested the hypothesis that A1 adenosine receptor (A1AR)
activation plays a role in sildenafil-induced cardioprotective signaling.
Methods and Results: Adult male C57BL-wild type (WT) mice or their corresponding
A1AR-knock out (KO) mice were pretreated (i.p.) with either sildenafil (0.71 mg/kg,
equivalent to 50 mg dose for 70 kg patient) or volume-matched saline. The selective A1AR
antagonist DPCPX (0.1 mg/kg, i.p.) was administered 30 min before sildenafil. The hearts
were isolated 24 hours later and subjected to 30 min global ischemia and 1 hr of
reperfusion in Langendorff mode. Infarct size was measured by computer morphometry of
TTC stained sections. Post-ischemic myocardial infarct size (Mean±SEM; % of risk area)
was reduced in C57BL-WT mice treated with sildenafil (5.6±0.9) versus saline group
(27.3±2.1; P<0.05; n=6/each). Sildenafil failed to precondition the A1AR-KO hearts
(31.6±1.9 vs. 32.3±1.5 with saline, p>0.05). Additionally, DPCPX treatment abolished the
infarct limiting effect of sildenafil (27.3±3.2, p<0.05). DPCPX alone had no effect on
infarct size as compared with the control group. No significant changes in left ventricular
pressure and heart rate were observed in sildenafil-treated group.
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Conclusion: The sildenafil-induced delayed protection against global ischemia/reperfusion
is mediated by signaling pathway involving the interaction of endogenous adenosine with
its A1 receptor.

INTRODUCTION
Adenosine receptor activation following PC protects the heart against reversible
and irreversible ischemic injury in multiple species and preparations (97,98). As described
in the previous section, our initial studies demonstrated the cardioprotective effect of
sildenafil in several animal species. The hypothesis behind these studies was that the
release of endogenous mediators such as adenosine, bradykinin or NO following sildenafil
treatment. This in turn could potentially trigger signaling pathways leading to
cardioprotection.
Since we previously demonstrated the importance of ERK activation and iNOS
upregulation in cardioprotection with sildenafil, and since other studies have already
demonstrated the link between A1AR and iNOS, we examined the possibility of A1AR
contribution to the PC-like effect afforded by sildenafil. We hypothesized that sildenafil,
through its hypotensive effects, would potentially lead to the release of adenosine from
cells into the interstitial fluid, thus making adenosine available to interact with its
receptors. This mimics, to a certain extent, the release of small amounts of adenosine
observed during brief episodes of ischemia that leads to PC against subsequent prolonged
ischemia. In the present study, we took advantage of adenosine A1 receptor knock-out
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mice and selective A1 receptor antagonist DPCPX to elucidate the role of A1AR in
inducing delayed cardioprotection in mice. The goals of the study are as follows:
1) to determine whether sildenafil could confer cardioprotective effects in the C57BL-WT
mice similar to ICR outbred mice shown previously; 2) to show if sildenafil confers
delayed cardioprotection in A1AR-KO mice and following inhibition of the receptor in
WT mice with the selective A1AR antagonist DPCPX; and 3) to demonstrate that
sildenafil induces protection against simulated ischemia/reoxygenation in mouse
cardiomyocytes derived from WT and A1AR-KO mice.

Materials and Methods
Animals

Adult male C57BL mice were supplied by The Jackson Laboratory (Bar Harbor,
ME. The body weight for these animals ranged between 27.1 and 32.7 g. A1AR-KO mice
were provided by The National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, Bethesda, MD 20592; PI Dr. Jurgen Schnermann.
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Langendorff Isolated Perfused Heart Preparation

The methodology of the Langendorff isolated perfused heart has been described in
previous chapters. The only difference in the current study in the use of left ventricular
developed pressure as opposed to ventricular contractile function. To obtain the developed
pressure, a left atrial incision was made to expose the mitral annulas through which a
water-filled latex balloon was passed into the left ventricle (LV). The balloon was attached
via polyethylene tubing to a Gould pressure transducer that was connected to a PowerLab
Acquisition System (ADInstruments 8SP, Australia). The balloon was inflated to adjust the
LV enddiastolic pressure (LVEDP) to _10 mmHg. Myocardial ischemic damage was
measured using multiple, independent end points of tissue injury. These included infarct
size, LV developed pressure (LVDP), LVEDP, rate-pressure product (RPP), heart rate, and
coronary flow by timed collection of the perfusate. LVDP was calculated by subtracting
LVEDP from the peak systolic pressure. RPP, an index of cardiac work, was calculated by
multiplying LVDP with heart rate. The hearts were not paced.
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Study Protocol

Mice were randomly assigned into one of the following groups:

Group I: (saline control, n=6): WT mice received 0.9 % saline, i.p.;
Group II: (saline control, n=6): A1AR-KO mice received 0.9% saline, i.p.;
Group III: (Sildenafil, n=6): Wt mice; pure sildenafil powder provided by Pfizer, Inc.was
dissolved in saline. This preparation was given as 0.71 mg/kg i.p. bolus, approximating,
on a mg/kg basis, the clinical dose of 50 mg administered to a 70 kg patient;
Group IV: (Sildenafil, n=6): A1AR-KO mice received 0.71 mg/kg sildenafil as in Group
III;
Group V: (DPCPX+sildenafil n=6): WT mice; treatment with DPCPX (0.1mg/kg) 30 min
prior to sildenafil treatment as in Group III
Group VI: (DPCPX+saline n=6): WT mice; treatment with DPCPX (0.1mg/kg) 30 min
prior to saline treatment as in Group I.

Twenty-four hours later, the hearts were isolated and following a 30 min stabilization
period, the hearts were subjected to 30 min no-flow normothermic global ischemia and 1
hr reperfusion.
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Another subset of mice was used for adult cardiomyocyte isolation as described later in
this section. The isolated cardiomyocytes were subjected to hypoxia/reoxygenation to
simulate ischemia/reperfusion in the intact heart. Different study groups were randomly
assigned in order to assess the role of sildenafil in cardioprotection in vitro as well as
evaluating the role of the A1AR in the sildenafil induced protection.

Isolation of adult mouse ventricular cardiomyocytes:

Adult male C57BL-WT (The

Jackson Laboratory, Bar Harbor, ME) or A1AR-KO mice (National Institute of Diabetes
and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20592; PI
Dr. Jurgen Schnermann) were used in this study. The animal experimental protocols were
approved by the Institutional Animal Care and Use committee of Virginia Commonwealth
University. The ventricular cardiomyocytes were isolated using an enzymatic technique
modified from the previously reported method (95,96). In brief, the animal was
anesthetized with pentobarbital sodium (100 mg/kg, i.p.) and heart was quickly removed.
Within 3 min, the aortic opening was cannulated onto a Langendorff perfusion system and
heart was retrogradely perfused (37oC) at a constant pressure of 55 mmHg for ~5 min with
a Ca2+-free bicarbonate-based buffer containing (in mM): 120 NaCl, 5.4 KCl, 1.2 MgSO4,
1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10 2,3-butanedione monoxime, and 5 taurine,
which was continuously bubbled with 95%O2 + 5%CO2. The enzymatic digestion was
commenced by adding collagenase type II (Worthington, 0.5 mg/mL each) and protease
type XIV (0.02 mg/mL) to the perfusion buffer and continued for ~15 min. 50 µM Ca2+
was then added in to the enzyme solution for perfusing the heart for another 10-15 min.
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The digested ventricular tissue was cut into chunks and gently aspirated with a transfer
pipette for facilitating the cell dissociation. The cell pellet was resuspended for a 3-step
Ca2+ restoration procedure (i.e. 125, 250, 500 µM Ca2+). The freshly isolated
cardiomyocytes were then suspended in minimal essential medium (Sigma catalogue# 6
M1018, pH 7.35-7.45) containing 1.2 mM Ca2+, 12 mM NaHCO3, 2.5% fetal bovine serum
and 1% penicillin-streptomycin. The cells were then plated onto the 35 mm cell culture
dishes, which were pre-coated with 20 µg/mL mouse laminin in PBS + 1% penicillinstreptomycin for 1 hour. The cardiomyocytes were cultured in the presence of 5% CO2 for
1 hour in a humidified incubator at 37oC, which allowed cardiomyocytes to attach to the
dish surface prior to the experimental protocol.

Experimental Protocol

The cultured cardiomyocytes were incubated under 37oC and 5% CO2, for 1 hour with or
without 1 µM sildenafil citrate powder, dissolved in distilled water. The drug solution was
filtered (0.45 µm pore size) before adding into cell medium. Cardiomyocytes were
subjected to SI for 40 minutes by replacing the cell medium with an “ischemia buffer”
which contained (in mM): 118 NaCl, 24 NaHCO3, 1.0 NaH2PO4, 2.5 CaCl2-2H2O, 1.2
MgCl2, 20 sodium lactate, 16 KCl, 10 2-deoxyglucose (pH adjusted to 6.2). In addition, the
cells were incubated under hypoxic conditions at 37oC during the entire SI period by
adjusting the tri-gas incubator to 1-2% O2 and 5% CO2. RO was accomplished by replacing
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the ischemic buffer with normal medium under normoxic conditions. Assessment of cell
necrosis and apoptosis was performed at 18 hours of RO.

Evaluation of Cell Viability:

Cell viability was assessed by trypan blue exclusion assay.

At the end of protocol, 20 µL of 0.4% trypan blue (Sigma-Aldrich) was added into the
culture dish. After ~5 min of equilibration, the cells were counted under microscope.

Statistics: All measurements are expressed as means ± SE. The data were analyzed by
either unpaired t-test or one-way ANOVA. If a significant value of F was obtained in
ANOVA, the Student-Newman-Keuls post hoc test was further used for pairwise
comparisons. Paired t-test was used to compare any pair of pre- and post-treatment values
for the same parameter. P < 0.05 was considered significant.

RESULTS

Cardiac Hemodynamics and Contractile Function:
There was no significant difference in the basal functional parameters (i.e. developed
LV pressure, rate-pressure product, and EDP) between the groups after 20 min
stabilization. During post-ischemia also, there was a significant increase in the rate
pressure product (Figure 1) only in the sildenafil-treated group. Post-ischemic coronary
flow was not significantly different among the groups.
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Myocardial Infarction:

Post-ischemic myocardial infarct size (Mean±SEM; % of risk area) was reduced in wild
type mice treated with sildenafil (5.6±0.9) versus saline group (27.3±2.1; P<0.05;
n=6/each) (Figure 2). On the other hand, sildenafil did not offer any protection in the
A1AR-KO mice (31.6±1.9 vs. 32.3±1.5 with saline, p>0.05). Moreover, the selective
A1AR antagonist DPCPX completely blocked the infarct-limiting effect of sildenafil in the
wild type mice (27.3±3.2, p<0.05). There was no significant difference in the infarct size
between the controls and the animals treated with DPCPX or DMSO, the solvent for
DPCPX.

Effect of Sildenafil on Cardiomyocyte Necrosis
Our method for cell preparations yielded a relatively high percentage of the
cardiomyocytes with rod shape morphology, which was similar to previously reported
studies (95,96).
After 40 min of SI and 18 hours of RO, the trypan blue positive cardiomyocytes reached
53±2.8%. However, prior treatment with sildenafil reduced the trypan blue positive cells as
compared with untreated SI-RO group (24.5±2.6, p<0.05, n=3; Fig 3). The A1AR selective
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antagonist, DPCPX, abolished the protective effect of sildenafil as shown by an increase in
the trypan blue positive cells which was not different from control (50.8±3.0).
Interestingly, in the cardiomyocytes obtained from A1AR-KO mice, sildenafil failed to
protect the myocytes against necrosis caused by H/R as compared with control (46.7±2.3
vs 51.9±4.4). DPCPX or its solvent DMSO alone had no effect on trypan blue positive cell
count.

Discussion

Since sildenafil causes a hypotensive response, it is possible that adenosine would
be released and consequently interacts with its receptors potentially leading to a
preconditioning-like effect. Accordingly, the previously reported cardioprotective effect of
sildenafil could be mediated by A1AR. In the present study, we used a reltively selective
approach by employing mice showing genetic deletion of the A1AR and we investigated
the role of the A1AR in the sildenafil-induced preconditioning-like effect. As our recent
results show, sildenafil did in fact confer powerful cardioprotection against I/R injury in an
isolated mouse heart model of I/R. This protection was abolished by both the selective
A1AR antagonist DPCPX and genetic deletion of A1AR. Furthermore, in the isolated
adult cardiomyocyte derived from wild-type mice, the trypan blue positive necrotic cells
were significantly lower in the sildenafil-treated group as compared with the saline treated
control myocytes. Also, sildenafil-induced protection was abolished by A1AR antagonist,
DPCPX and cells obtained from A1AR-KO mouse cardiomyocytes treated with sildenafil.
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Adenosine receptor subtypes, including the A1 and A2a receptors, have been reported to
couple to the ERK pathway in both cardiac and noncardiac tissues. It has also been
reported that the beneficial effects of adenosine A2a receptor activation during reperfusion
appear to be due to ERK activation (107). However, thusfar, there have been no studies
examining whether adenosine receptor PC is mediated via ERK. Although the results of a
significant number of studies suggest that ERK activation during ischemia-reperfusion is
beneficial, there are additional reports suggesting otherwise. The discrepancies in the exact
role of ERK activation in myocardial ischemia-reperfusion may be due to the specific
stimulus and the duration of ERK activation. Despite the key role for mitochondria in
mediating the beneficial effects of PC, as well as contributing to reperfusion oxidative
stress, and a report that ERK isoforms are present in murine heart mitochondrial fractions
(108), there have been no reports examining mitochondrial ERK activation during PC or
myocardial ischemia/reperfusion.

Our present results raise a very interesting topic as to how sildenafil could afford
cardiomyocyte protection against H/R in the absence of the hypotensive effect. If the mild
drop in blood pressure due to cGMP accumulation is what caused adenosine release in vivo
as we initially hypothesized, then there probably is some other mechanism through which
sildenafil is effective against necrosis from H/R in vitro. It is possible that cGMP formed
after treatment with sildenafil somehow affects the A1AR sensitivity and thus allows more
adenosine to re-enter the cell after its release during hypoxia and thus generating a
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preconditioning-like effect. More research is needed to address this interesting finding and
further investigate the exact cause-and-effect relationship between sildenafil and the
A1AR.
In conclusion, we have demonstrated in the current study that genetic deletion of A1AR
abolishes the cardioprotective effects of ischemic preconditioning as well as
pharmacological preconditioning with the PDE-5 inhibitor sildenafil. Our findings do in
fact corroborate a key role of A1AR activation in the subcellular mechanisms of
myocardial protection against I/R injury.
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Figure Legends

Figure 1.

Experimental protocol showing the various groups.

Figure 2.

Effect of sildenafil, DPCPX, and genetic deletion of A1AR on ventricular

functional recovery following global ischemia-reperfusion.

Figure 3. TOP: Representative heart sections showing infarction (white) with 10% TTC
staining. More viable tissue (red) is prominent in the sildenafil-treated WT mice as
compared to the A1AR-KO mice and DPCPX-treated mice.
BOTTOM: Effect of sildenafil on myocardial infarct size: role of A1AR. Isolated perfused
hearts were subjected to 30 min global ischemia and 1hr reperfusion in Langendorff mode.
Values are means ± SE (n = 6 heart samples per group). Group III (WT) and IV (A1ARKO) received sildenafil (0.71 mg/kg, ip). Group V received DPCPX (0.1 mg/kg) 30 min
before sildenafil treatment. Group (I, II) and (VI) served as controls for sildenafil and
DPCPX, respectively. *P < 0.05 vs. sildenafil+WT.

Figure 4. Necrotic index using trypan blue in adult ventricular cardiomyocytes obtained
from wild type and A1AR-knock out mice.

Figure 5. Digital photo showing an adult mouse heart being perfused in Langendorff
mode.
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Figure 2
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Chapter 8
General Discussion

Phosphodiesterase type-5 (PDE-5) inhibitors

PDE-5 inhibitors are a new class of vasoactive drugs that have been developed for
treatment of ED in men. Their main mechanism of action is through the active inhibition of
PDE-5 enzyme thus allowing accumulation of cGMP resulting in smooth muscle
relaxation in the penis. So far, there are 11 known families of PDEs shown to exist in
mammalian tissues. Even though PDEs are expressed in all tissues, the distribution of the
various isoforms may differ among various tissues and cell types. These enzymes play a
key role in modulating diverse physiological processes.
Sildenafil citrate (ViagraTM) is the first oral agent approved for treatment of ED in men. Its
chemical structure is similar to that of cGMP and therefore inhibits PDE-5 by binding to
the cGMP-catalytic sites (Corbin and Francis, 2002), resulting in the accumulation of
cGMP in the erectile tissue.

Cardioprotection with sildenafil against I/R injury

For a little over three years now, sildenafil has been investigated as a candidate for
pharmacological PC against I/R injury in animal models. Due to its potent inhibition of
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PDE-5, we hypothesized that such vasodilatory effect caused by cGMP in the vascular
smooth muscle bed may potentially result in PC-like effect through affecting various
pathways implicated in PC. This pioneering work was initiated in our lab and was first
reported in 2002 (chapter 2). More research was conducted to elucidate the mechanism
through which sildenafil could confer powerful acute and delayed PC-like effects.

First, our results from the first study indicated the importance of mitoKATP channel
opening in the cardioprotection afforded by sildenafil when administered at a clinically
relevant dose; 0.71 mg/kg that was based on a 50 mg sildenafil tablet given to a 70 kg
patient as previously discussed (chapters 2, 3,4,5,6 and 7). This was shown by the ability
of 5-HD, a selective mitoKATP channel blocker, to completely abolish the protective effect
of sildenafil in our well-established rabbit model. Several studies have now conclusively
demonstrated that opening mitoKATP channels plays an important role in ischemic as well
as pharmacological preconditioning in the heart. KATP channels were first identified by
cardiovascular physiology studies as causing vascular smooth muscle relaxation in either
large or small arteries or as having a negative inotropic effect on cardiac myocytes. In
addition, activation of these channels seems to occur as a response to decreased
intracellular ATP levels, which is normally achieved within a few minutes after the onset
of ischemia. Because KATP channels act as an inward rectifier when activated, these effects
could be caused by an increase of the depolarization threshold that reduces excitation of
either vascular smooth muscle or cardiac myocytes followed by vasodilation and
shortening of the action potential duration, respectively, which finally lead to intracellular
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Ca2+ unloading and, as a result, reduced metabolic demand. Since these phenomena
resemble the acute cardiac responses and cardioprotection afforded by ischemic PC, it has
been postulated that mitoKATP channels might be one of the critical effectors of both
ischemic and pharmacological preconditioning.
In the rabbit studies (chapters 2,4 and 5), sildenafil caused an intense effect on the
hemodynamics. However, this profound drop in blood pressure bounced back to baseline
value within 5 minutes post treatment with sildenafil. Despite these pressure variations,
heart rate was not considerably affected by sildenafil administration.
In chapter 3, we further investigate the mechanism(s) through which sildenafil could cause
a reduction in infarct size following I/R in the rabbit heart. Since PKC is a key player in
PC, and translocation of some of its various isoforms is believed to alter several subcellular
pathways including mitoKATP channel opening, we sought to investigate the role of PKC in
the sildenafil induced cardioprotection. The PKC inhibitor, chelerythrine, blocked the PClike effect of sildenafil in rabbits (chapter 3). Furthermore, activation, i.e., translocation of
PKC-α, -θ and -δ isoforms from cytosol to the membrane fraction after treatment with
sildenafil was demonstrated by Western blot analysis. On the other hand, no change in
PKC-β and -ε isoforms was observed.
In chapter 4, we examined the cardioprotective effects of sildenafil in infant rabbits. Each
year, more than 25,000 children endure corrective heart surgery for congenital
cardiovascular disease. These infants are at risk for myocardial ischemia during
cardiopulmonary bypass, circulatory arrest or low flow states which are inevitable
components of the procedure (Rafiee et al., 2003). Despite the data supporting the higher
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flexibility of the infant myocardium to ischemic injury as compared to adults, the infant
heart responds quite differently to cardiovasular drugs, stress, and changes in
hemodynamics (Lewin et al., 1998; Wernovsky et al., 2001). The procedures currently
used in infants are not without limitations, such as poor functional recovery and even
mortality. For this reason, there is a great necessity for developing pharmacological agents
to be used as adjunct therapy along with surgical intervention in order to minimize, if not
eradicate, the side effects shown so far. In this respect, we examined the effect of sildenafil
on infarct size reduction as well as functional recovery following I/R in 8-week old infant
rabbits (chapter 5).
In addition to monitoring the hemodynamic changes as an indication of LV function , we
assessed the left ventricular cardiac output (LVCO) and aortic velocity time integral (VTI)
using trans-esophageal echocardiography (TEE). Our results were analogous to those
obtained from our adult rabbit experiments. We found that sildenafil could confer
cardioprotection against I/R in the infant rabbit heart. Both the control and sildenafiltreated groups had similar LVCO and aortic VTI at baseline. However, as the TEE results
indicated, only the sildenafil-treated group showed enhanced aortic VTI and LVCO 30 min
following ischemia. A descent in both values was reported at 3 hr of reperfusion in all
groups, but it was not statistically significant in the sildenafil-treated group.
Other studies, also from our lab, were conducted using isolated mouse hearts perfused in
Langendorff mode as previously described (chapters 3,6 and 7). Our goal was to further
elucidate the mechanism of action of sildenafil in cardioprotection.
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NO has been long implicated as an essential trigger and mediator of delayed PC. It has
been also shown to be involved in physiological as well as pharmacologival PC. NO is
synthesized by 3 isoforms of NO synthases (NOS), specifically, nNOS, iNOS and eNOS.
Since it has been shown that NO derived from iNOS is the mediator of delayed PC, we
tested the hypothesis that sildenafil treatment has an up-regulatory effect on iNOS leading
to increased NO production. Our results showed a significant reduction in infarct size
following global I/R in the sildenafil-treated mice as compared to the corresponding
controls 24 hr post-treatment. Also, the infarct-sparing effect of sildenafil was abolished by
the selective iNOS inhibitor, 1400W, which had no effect on infarct size when administered
alone. Sildenafil treatment did not alter pre- or post-ischemic coronary flow, indicating
that its cardioprotective effect may be independent of its vasodilatory effect in the delayed
phase. RT-PCR showed a transient increase in the levels of both eNOS and iNOS, peaking
at 45 minutes (eNOS) and 2 hours (iNOS) after sildenafil treatment and returning to
baseline levels several hours later (chapter 3), and this increase; however, was more
profound for iNOS mRNA. Moreover, Western blot analysis revealed a significant
increase in cardiac expression of iNOS and eNOS proteins 24 hours after sildenafil
treatment. These findings confirm that iNOS mediates the sildenafil-induced delayed PC
in mice.
The mitogen-activated protein kinase (MAPK) family has been associated with ischemic
PC. The results; however, have been divisive. Activation of p38 by anisomycin mimicked
PC and delayed cardioprotection in the isolated perfused hearts (Zhao et al., 2001). In the
MAPK family, the p42/p44-MAPK or ERK cascade appears to mediate cell growth and
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survival signals in many cell types.

Sustained activation of p42/p44-MAPK during

simulated 'reperfusion' following sublethal simulated ischemia mediates PC in
cardiomyocytes independent of transient activation of p38 MAPK (Punn et al., 2000). Our
preliminary results (chapter 6) have shown that selective inhibition of ERK by PD98059
completely abolished the delayed protective effect of sildenafil whereas p38 MAPK
inhibitor SB203580 failed to block the protection. These results were further supported by
increased phosphorylation of p44/42 but not p38 in sildenafil treated hearts. Furthermore,
PD98059 treatment prior to sildenafil blocked the increase of iNOS protein 24 hr later, as
shown by Western blot analysis, indicating that sildenafil upregulates iNOS through ERK
phosphorylation (chapter 6).
Most recently, we tested the hypothesis that the adenosine A1 receptor plays a role in PC
with sildenafil. The reason behind this study was that role of A1AR in PC has been
extensively studied, but the results have been inconclusive due to the limitations of the
A1AR antagonists. As a result of myocardial ischemia, there is an immediate depletion in
the ATP that is available for the cardiac cells and as a consequence adenosine is released to
interact with its receptors. In this respect, it was believed that brief episodes of I/R would
cause the release of adenosine and allow the interaction with its receptors to “precondition”
the myocardium against future ischemic insults. Moreover, intracoronary infusion of
adenosine in the isolated rabbit heart or CCPA in the isolated mouse heart prior to
sustained I/R demonstrated a marked decrease in infarct size when compared to control
animals. Due to the recent availability of A1AR-KO mice, the role of this receptor could
be further examined. For this reason, we tested the role of A1AR in the infarct-limiting
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effect of sildenafil. Our results demonstrated that the sildenafil-induced delayed protection
was abolished in the intact heart as well as adult myocytes derived from adenosine A1
receptor knock-out mice suggesting an essential role of A1 receptor in protection.
Taken together, these studies suggest that sildenafil is a powerful tool to reduce I/R injury
in the animal models studied thus far. The ongoing research effort from our lab provided a
deeper perspective for understanding the signaling mechanisms of cardioprotection
induced by sildenafil, apart from its well known function in causing cGMP accumulation
in the vascular smooth muscle bed. All these findings could be summarized as follows:
1) increased expression of nitric oxide synthases, 2) activation of kinases (such as PKC and
ERK), 3) opening of mitochondrial KATP channels, and 4) activation of A1AR.

Conclusion and Future Directions

Since cardiovascular disease remains the number one cause of morbidity and
mortality in the western world, it is necessary to develop novel pharmacological agents to
be used as adjunct therapy in addition to the widely practiced surgical intervention. These
invasive interventions are not without limitations and risks that might further damage an
ischemic heart. Thus far, all the pharmacological agents that showed excellent
cardioprotection in the animal models failed to do so to the same extent in human subjects.
Since sildenafil is FDA approved, the overall safety margin of this drug has been well
established. It is possible, due to its wide mechanism of action on the cellular and
molecular level, that sildenafil may potentially succeed in conferring a PC-like effect
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clinically in a similar fashion to the experimental setting. Therefore, vigilant clinical
studies are needed to examine the role of sildenafil in PC in patients with ischemic heart
disease. Preliminary experimental data from our lab (data not shown) have shown that
another PDE-5 inhibitor, Vardenafil, exerts similar PC-like cardioprotective effects in the
rabbit heart. Future clinical research is required to determine the safety and efficacy of
sildenafil and other FDA-approved PDE-5 inhibitors in management of patients with
coronary artery disease and to launch a novel cardioprotective strategy against I/R injury.
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